Tumor microenvironment and therapeutic response
•Tumor microenvironment (TME) influences therapeutic response and clinical outcome.•TME mediated resistance results from continuous crosstalk between tumor cells and stroma.•Targeting TME compartments could improve the effectiveness of current treatment. The tumor microenvironment significantly infl...
Saved in:
| Published in: | Cancer letters Vol. 387; pp. 61 - 68 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Ireland
Elsevier B.V
28.02.2017
Elsevier Limited |
| Subjects: | |
| ISSN: | 0304-3835, 1872-7980 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | •Tumor microenvironment (TME) influences therapeutic response and clinical outcome.•TME mediated resistance results from continuous crosstalk between tumor cells and stroma.•Targeting TME compartments could improve the effectiveness of current treatment.
The tumor microenvironment significantly influences therapeutic response and clinical outcome. Microenvironment-mediated drug resistance can be induced by soluble factors secreted by tumor or stromal cells. The adhesion of tumor cells to stromal fibroblasts or to components of the extracellular matrix can also blunt therapeutic response. Microenvironment-targeted therapy strategies include inhibition of the extracellular ligand–receptor interactions and downstream pathways. Immune cells can both improve and obstruct therapeutic efficacy and may vary in their activation status within the tumor microenvironment; thus, re-programme of the immune response would be substantially more beneficial. The development of rational drug combinations that can simultaneously target tumor cells and the microenvironment may represent a solution to overcome therapeutic resistance. |
|---|---|
| AbstractList | •Tumor microenvironment (TME) influences therapeutic response and clinical outcome.•TME mediated resistance results from continuous crosstalk between tumor cells and stroma.•Targeting TME compartments could improve the effectiveness of current treatment.
The tumor microenvironment significantly influences therapeutic response and clinical outcome. Microenvironment-mediated drug resistance can be induced by soluble factors secreted by tumor or stromal cells. The adhesion of tumor cells to stromal fibroblasts or to components of the extracellular matrix can also blunt therapeutic response. Microenvironment-targeted therapy strategies include inhibition of the extracellular ligand–receptor interactions and downstream pathways. Immune cells can both improve and obstruct therapeutic efficacy and may vary in their activation status within the tumor microenvironment; thus, re-programme of the immune response would be substantially more beneficial. The development of rational drug combinations that can simultaneously target tumor cells and the microenvironment may represent a solution to overcome therapeutic resistance. The tumor microenvironment significantly influences therapeutic response and clinical outcome. Microenvironment-mediated drug resistance can be induced by soluble factors secreted by tumor or stromal cells. The adhesion of tumor cells to stromal fibroblasts or to components of the extracellular matrix can also blunt therapeutic response. Microenvironment-targeted therapy strategies include inhibition of the extracellular ligand-receptor interactions and downstream pathways. Immune cells can both improve and obstruct therapeutic efficacy and may vary in their activation status within the tumor microenvironment; thus, re-programme of the immune response would be substantially more beneficial. The development of rational drug combinations that can simultaneously target tumor cells and the microenvironment may represent a solution to overcome therapeutic resistance. Highlights • Tumor microenvironment (TME) influences therapeutic response and clinical outcome. • TME mediated resistance results from continuous crosstalk between tumor cells and stroma. • Targeting TME compartments could improve the effectiveness of current treatment. |
| Author | Dai, Yun Wu, Ting |
| Author_xml | – sequence: 1 givenname: Ting surname: Wu fullname: Wu, Ting – sequence: 2 givenname: Yun surname: Dai fullname: Dai, Yun email: daiyun1@medmail.com.cn |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26845449$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVkl9rFDEUxYNU7Lb6DUQWfPFltjeTP5MRKUixKhR8sD6Hu5k7mHUmWZNMod_eGbalUJDqU7jwO-eSc-4JOwoxEGOvOWw4cH222zgMA5VNPU8b4BuQ4hlbcdPUVdMaOGIrECArYYQ6Zic57wBAyUa9YMe1NlJJ2a7Y2fU0xrQevUuRwo1PMYwUyhpDty4_KeGepuLdOlHex5DpJXve45Dp1d17yn5cfrq--FJdffv89eLjVeU08FKJ3vFetL3qdSec0q3DtkNeA2HfGInYmEb3W1RCgHMGt4ASGkJBals7AeKUvTv47lP8PVEudvTZ0TBgoDhly41qpdHQ_gtaa61MK9SMvn2E7uKUwvyRxVAJ0Fou1Js7atqO1Nl98iOmW3uf2gy8PwBzaDkn6q3zBYuPoST0g-Vgl4rszh4qsktFFridK5rF8pH43v8J2flBRnPqN56Szc5TcNT5RK7YLvr_NXCDD97h8ItuKT8EYXNtwX5fjme5Ha4FAFdLLB_-bvD0_j-C-dR3 |
| CitedBy_id | crossref_primary_10_1007_s00262_020_02649_x crossref_primary_10_3389_fimmu_2022_999549 crossref_primary_10_1007_s10142_022_00957_2 crossref_primary_10_1002_mco2_6 crossref_primary_10_3389_fphar_2022_1046818 crossref_primary_10_1186_s12859_024_05835_1 crossref_primary_10_3390_cancers15051360 crossref_primary_10_3390_cells10061472 crossref_primary_10_1111_cns_70117 crossref_primary_10_1016_j_bioactmat_2024_05_009 crossref_primary_10_1101_gr_275308_121 crossref_primary_10_1038_s41598_025_13665_1 crossref_primary_10_1016_j_pccm_2022_11_001 crossref_primary_10_1016_j_biomaterials_2020_120429 crossref_primary_10_2147_IJGM_S335266 crossref_primary_10_3389_fonc_2022_1049888 crossref_primary_10_1016_j_oooo_2024_02_016 crossref_primary_10_1007_s00428_024_03755_2 crossref_primary_10_1089_ars_2023_0007 crossref_primary_10_1016_j_jconrel_2025_113998 crossref_primary_10_3390_cancers12030717 crossref_primary_10_3389_fimmu_2021_802080 crossref_primary_10_3389_fimmu_2020_01600 crossref_primary_10_1515_med_2023_0863 crossref_primary_10_1016_j_blre_2020_100786 crossref_primary_10_1038_s41698_025_00866_0 crossref_primary_10_1002_cam4_5383 crossref_primary_10_1007_s12094_020_02450_3 crossref_primary_10_1002_adhm_202000690 crossref_primary_10_3389_fimmu_2023_1183465 crossref_primary_10_3389_fcell_2021_761350 crossref_primary_10_3389_fonc_2020_577072 crossref_primary_10_1016_j_jpha_2025_101408 crossref_primary_10_1111_1759_7714_14873 crossref_primary_10_1089_ars_2023_0236 crossref_primary_10_1186_s12885_023_11265_8 crossref_primary_10_1186_s12943_019_1089_9 crossref_primary_10_1093_stmcls_sxac036 crossref_primary_10_3390_cells8080926 crossref_primary_10_1007_s13402_018_00418_8 crossref_primary_10_1038_s41419_020_03189_z crossref_primary_10_3390_cells13090730 crossref_primary_10_2147_IJGM_S335052 crossref_primary_10_1038_s41596_020_00421_0 crossref_primary_10_1016_j_addr_2022_114365 crossref_primary_10_1016_j_ejphar_2024_176639 crossref_primary_10_1002_cam4_70992 crossref_primary_10_3390_cancers14010190 crossref_primary_10_3389_fonc_2019_01509 crossref_primary_10_1002_adfm_202206300 crossref_primary_10_1186_s12935_023_03003_8 crossref_primary_10_7717_peerj_15203 crossref_primary_10_3389_fonc_2020_616717 crossref_primary_10_1038_s41598_024_57714_7 crossref_primary_10_1186_s12943_020_01186_6 crossref_primary_10_3390_cancers17050785 crossref_primary_10_3389_fimmu_2025_1560998 crossref_primary_10_1186_s12967_021_03053_4 crossref_primary_10_1111_jcmm_70424 crossref_primary_10_1137_22M1497729 crossref_primary_10_1016_j_tranon_2021_101309 crossref_primary_10_1080_01616412_2023_2287340 crossref_primary_10_1016_j_canlet_2025_217850 crossref_primary_10_3389_fbioe_2021_680315 crossref_primary_10_2147_CMAR_S279684 crossref_primary_10_1007_s00262_022_03143_2 crossref_primary_10_1016_j_apmt_2022_101628 crossref_primary_10_3389_fonc_2022_824166 crossref_primary_10_3389_fgene_2021_723001 crossref_primary_10_1186_s12935_024_03625_6 crossref_primary_10_3389_fonc_2020_580029 crossref_primary_10_1186_s12885_025_13534_0 crossref_primary_10_1097_MD_0000000000033546 crossref_primary_10_1038_s41419_023_05914_w crossref_primary_10_3389_fimmu_2021_800928 crossref_primary_10_1016_j_jid_2020_06_034 crossref_primary_10_1016_j_labinv_2025_104222 crossref_primary_10_1016_j_acra_2023_12_015 crossref_primary_10_1111_cas_15131 crossref_primary_10_1038_s41401_024_01355_z crossref_primary_10_1186_s12967_020_02267_2 crossref_primary_10_2147_OTT_S274754 crossref_primary_10_12998_wjcc_v9_i16_3880 crossref_primary_10_1016_j_jtbi_2025_112231 crossref_primary_10_1186_s13045_025_01692_4 crossref_primary_10_3390_biomedicines13081899 crossref_primary_10_1016_j_ijbiomac_2025_143056 crossref_primary_10_1038_s41598_024_83714_8 crossref_primary_10_1016_j_bbcan_2025_189344 crossref_primary_10_3389_fendo_2019_00547 crossref_primary_10_3389_fonc_2024_1363695 crossref_primary_10_1186_s12859_021_04456_2 crossref_primary_10_1016_j_jpha_2025_101218 crossref_primary_10_1038_s41598_023_35633_3 crossref_primary_10_1002_lary_31901 crossref_primary_10_3389_fonc_2023_1098357 crossref_primary_10_1016_j_heliyon_2024_e26604 crossref_primary_10_3390_ijms24129854 crossref_primary_10_20538_1682_0363_2022_1_171_182 crossref_primary_10_1016_S1470_2045_19_30172_X crossref_primary_10_1016_j_canlet_2023_216184 crossref_primary_10_1016_j_omto_2022_08_003 crossref_primary_10_1016_j_canlet_2023_216182 crossref_primary_10_1007_s12672_025_02093_2 crossref_primary_10_3390_cancers14092289 crossref_primary_10_1097_MD_0000000000025909 crossref_primary_10_1097_MD_0000000000031382 crossref_primary_10_1016_j_ajpath_2019_10_018 crossref_primary_10_1186_s12920_022_01419_1 crossref_primary_10_2147_IJGM_S337876 crossref_primary_10_3724_abbs_2024111 crossref_primary_10_1109_JBHI_2024_3387930 crossref_primary_10_1016_j_talanta_2022_123971 crossref_primary_10_1186_s12943_021_01368_w crossref_primary_10_1016_j_heliyon_2024_e24455 crossref_primary_10_1002_ppsc_202100048 crossref_primary_10_1038_s41392_023_01408_5 crossref_primary_10_3389_fcell_2023_1166916 crossref_primary_10_3390_cancers14174251 crossref_primary_10_1111_odi_15130 crossref_primary_10_1155_2024_2177516 crossref_primary_10_3389_fimmu_2023_1224904 crossref_primary_10_1007_s12274_022_5296_0 crossref_primary_10_1038_s41598_022_20162_2 crossref_primary_10_3389_fimmu_2020_582828 crossref_primary_10_2147_IJN_S275938 crossref_primary_10_1038_s41598_024_67547_z crossref_primary_10_1038_s41392_022_01102_y crossref_primary_10_1002_jum_15900 crossref_primary_10_1155_2022_9117205 crossref_primary_10_1038_s41467_023_40954_y crossref_primary_10_3389_fcell_2021_703415 crossref_primary_10_3389_fonc_2022_1099965 crossref_primary_10_1038_s41597_023_02032_2 crossref_primary_10_1186_s40164_023_00394_2 crossref_primary_10_1007_s00251_022_01273_6 crossref_primary_10_1007_s12010_022_04098_x crossref_primary_10_1242_dmm_049457 crossref_primary_10_1002_ctm2_1101 crossref_primary_10_1002_mco2_70202 crossref_primary_10_1007_s12672_025_02201_2 crossref_primary_10_1007_s11706_021_0543_y crossref_primary_10_1007_s12094_022_03000_9 crossref_primary_10_3390_cancers16040710 crossref_primary_10_3390_ijms24043703 crossref_primary_10_1002_mog2_68 crossref_primary_10_1038_s41417_020_00273_6 crossref_primary_10_1007_s10565_023_09808_7 crossref_primary_10_1007_s00277_020_04389_5 crossref_primary_10_1038_s41598_024_79417_9 crossref_primary_10_1016_j_neuropharm_2024_110164 crossref_primary_10_3389_fonc_2025_1609501 crossref_primary_10_1016_j_yexcr_2024_114395 crossref_primary_10_1007_s12672_025_01817_8 crossref_primary_10_1002_smtd_202401192 crossref_primary_10_1039_D1NR03387E crossref_primary_10_3389_fonc_2022_878849 crossref_primary_10_1186_s13046_020_01808_3 crossref_primary_10_3390_jcm12030861 crossref_primary_10_1016_j_canlet_2023_216126 crossref_primary_10_1002_cam4_4203 crossref_primary_10_3389_fonc_2021_724655 crossref_primary_10_1002_cac2_70027 crossref_primary_10_3389_fmolb_2021_760031 crossref_primary_10_3390_cancers15245779 crossref_primary_10_1111_iju_15042 crossref_primary_10_3389_fimmu_2022_724139 crossref_primary_10_1002_advs_202413367 crossref_primary_10_1177_15330338211046432 crossref_primary_10_1016_j_cbi_2023_110626 crossref_primary_10_1016_j_oraloncology_2023_106532 crossref_primary_10_1038_s41392_020_00419_w crossref_primary_10_1016_j_intimp_2024_113208 crossref_primary_10_3390_ijms242216188 crossref_primary_10_1002_advs_202207697 crossref_primary_10_1007_s10238_022_00955_5 crossref_primary_10_3389_fphar_2022_919636 crossref_primary_10_3389_fgene_2022_840348 crossref_primary_10_3389_fonc_2021_639059 crossref_primary_10_1016_j_cytogfr_2023_07_007 crossref_primary_10_3389_fmolb_2023_1182083 crossref_primary_10_1007_s10528_023_10645_w crossref_primary_10_1042_BSR20203804 crossref_primary_10_2174_0109298673290101240223074545 crossref_primary_10_3389_fonc_2021_704001 crossref_primary_10_3390_ma15207057 crossref_primary_10_2147_IJWH_S537092 crossref_primary_10_1186_s12951_022_01476_9 crossref_primary_10_3390_ijms26115394 crossref_primary_10_1038_s41416_023_02336_5 crossref_primary_10_1038_s41467_023_41318_2 crossref_primary_10_1186_s12935_021_02000_z crossref_primary_10_1007_s12032_023_02295_0 crossref_primary_10_3389_fphar_2020_01177 crossref_primary_10_1186_s12935_022_02626_7 crossref_primary_10_1016_j_oraloncology_2020_104972 crossref_primary_10_1186_s13045_025_01665_7 crossref_primary_10_1016_j_jare_2025_07_027 crossref_primary_10_1155_2023_9226712 crossref_primary_10_1016_j_lfs_2023_122387 crossref_primary_10_3390_ph18050746 crossref_primary_10_1007_s10555_023_10086_2 crossref_primary_10_3389_fbioe_2021_670124 crossref_primary_10_3390_nu16244338 crossref_primary_10_1038_s41419_022_04501_9 crossref_primary_10_3390_cells13171428 crossref_primary_10_3389_fphar_2021_706240 crossref_primary_10_1371_journal_pone_0252099 crossref_primary_10_3390_cancers15174224 crossref_primary_10_1002_jcp_31180 crossref_primary_10_1002_jgm_3643 crossref_primary_10_3389_fgene_2021_646362 crossref_primary_10_1186_s12964_023_01129_w crossref_primary_10_1039_D3BM02133E crossref_primary_10_3389_fimmu_2022_1026701 crossref_primary_10_1038_s41598_025_99383_0 crossref_primary_10_1016_j_biopha_2023_116014 crossref_primary_10_3389_fneur_2024_1387986 crossref_primary_10_1186_s13046_021_01893_y crossref_primary_10_1016_j_canlet_2023_216166 crossref_primary_10_1186_s12883_023_03058_0 crossref_primary_10_1016_j_csbj_2021_08_047 crossref_primary_10_1016_j_lfs_2020_118248 crossref_primary_10_1016_j_intimp_2021_108258 crossref_primary_10_2147_IJGM_S331752 crossref_primary_10_3390_cells13030256 crossref_primary_10_3389_fimmu_2022_865964 crossref_primary_10_1097_MD_0000000000033149 crossref_primary_10_1111_odi_14897 crossref_primary_10_1186_s13045_024_01535_8 crossref_primary_10_1007_s12015_025_10870_3 crossref_primary_10_3389_fimmu_2020_585034 crossref_primary_10_1007_s10620_024_08365_1 crossref_primary_10_1016_j_bbadis_2024_167017 crossref_primary_10_1111_jcmm_70212 crossref_primary_10_3892_ol_2022_13644 crossref_primary_10_1007_s00432_019_03108_6 crossref_primary_10_3389_fcell_2024_1369597 crossref_primary_10_1186_s12935_024_03575_z crossref_primary_10_1186_s12967_024_06001_0 crossref_primary_10_1016_j_biopha_2022_113927 crossref_primary_10_1186_s13578_023_01059_7 crossref_primary_10_3389_fphar_2023_1320028 crossref_primary_10_1038_s41598_020_77657_z crossref_primary_10_1007_s00018_020_03696_4 crossref_primary_10_1111_jcmm_17625 crossref_primary_10_1002_cam4_3561 crossref_primary_10_3389_fgene_2025_1533817 crossref_primary_10_1016_j_cclet_2022_107753 crossref_primary_10_1111_jcmm_15443 crossref_primary_10_1186_s12935_022_02483_4 crossref_primary_10_1155_2022_6419695 crossref_primary_10_3390_ph15050605 crossref_primary_10_1038_s41419_023_06119_x crossref_primary_10_3389_fmed_2023_1174764 crossref_primary_10_3389_fonc_2020_586414 crossref_primary_10_3389_fonc_2025_1598934 crossref_primary_10_1186_s12885_024_13415_y crossref_primary_10_1016_j_matdes_2022_111435 crossref_primary_10_1080_17425247_2021_1882992 crossref_primary_10_4251_wjgo_v13_i1_37 crossref_primary_10_1007_s11033_022_07553_4 crossref_primary_10_3389_fimmu_2020_603640 crossref_primary_10_1016_j_semcancer_2021_03_014 crossref_primary_10_3390_cancers15245759 crossref_primary_10_1186_s12920_021_00966_3 crossref_primary_10_3389_fonc_2021_654689 crossref_primary_10_3389_fimmu_2019_02872 crossref_primary_10_3389_fonc_2021_640080 crossref_primary_10_1016_j_addr_2021_114003 crossref_primary_10_1016_j_addr_2021_114004 crossref_primary_10_1016_j_bbcan_2024_189205 crossref_primary_10_3389_fimmu_2023_1223650 crossref_primary_10_3389_fneur_2025_1549465 crossref_primary_10_3389_fimmu_2022_1034992 crossref_primary_10_3390_cancers16183222 crossref_primary_10_3389_fonc_2022_998274 crossref_primary_10_1002_orm2_70008 crossref_primary_10_1016_j_hpb_2020_03_011 crossref_primary_10_1016_j_drup_2023_100962 crossref_primary_10_1155_2021_3284186 crossref_primary_10_1002_cnr2_1965 crossref_primary_10_3389_fmolb_2022_773662 crossref_primary_10_1016_j_heliyon_2024_e36819 crossref_primary_10_3389_fonc_2020_564306 crossref_primary_10_1080_21655979_2021_1927560 crossref_primary_10_1155_2022_7654937 crossref_primary_10_3389_fcell_2021_672248 crossref_primary_10_1038_s41467_024_47737_z crossref_primary_10_3389_fgene_2022_818378 crossref_primary_10_3389_fonc_2022_1042118 crossref_primary_10_1186_s12885_021_08447_7 crossref_primary_10_1186_s12885_023_11249_8 crossref_primary_10_1007_s00018_023_05054_6 crossref_primary_10_4103_jcrt_jcrt_91_21 crossref_primary_10_1186_s40001_023_01422_x crossref_primary_10_1186_s12957_020_01921_9 crossref_primary_10_3389_fonc_2023_1162653 crossref_primary_10_1016_j_biomaterials_2022_121512 crossref_primary_10_1016_j_bbagen_2023_130439 crossref_primary_10_3389_fimmu_2025_1583044 crossref_primary_10_3389_fmed_2025_1614012 crossref_primary_10_3389_fimmu_2021_791535 crossref_primary_10_3389_fimmu_2021_648182 crossref_primary_10_1038_s41598_024_57402_6 crossref_primary_10_1038_s41419_018_0808_2 crossref_primary_10_3389_fonc_2022_956270 crossref_primary_10_1039_D3NR01722B crossref_primary_10_3389_fgene_2022_922472 crossref_primary_10_1016_j_colsurfb_2020_111104 crossref_primary_10_1016_j_intimp_2020_106641 crossref_primary_10_3390_cancers13040847 crossref_primary_10_1016_j_actbio_2024_01_037 crossref_primary_10_1016_j_canlet_2021_02_013 crossref_primary_10_1038_s41418_024_01317_2 crossref_primary_10_1186_s12931_023_02408_3 crossref_primary_10_1016_j_biopha_2021_112504 crossref_primary_10_1016_j_bbrep_2025_102205 crossref_primary_10_1016_j_freeradbiomed_2021_10_010 crossref_primary_10_3389_fimmu_2023_1123841 crossref_primary_10_1016_j_lfs_2021_119461 crossref_primary_10_1016_j_canlet_2023_216413 crossref_primary_10_3389_fimmu_2025_1631449 crossref_primary_10_1142_S0192415X21500270 crossref_primary_10_3389_fphar_2022_1040847 crossref_primary_10_1177_11795549211035540 crossref_primary_10_1002_cai2_113 crossref_primary_10_3390_cancers14225571 crossref_primary_10_1007_s12672_024_01573_1 crossref_primary_10_1186_s12885_023_11589_5 crossref_primary_10_3389_fonc_2022_927706 crossref_primary_10_1111_nan_70027 crossref_primary_10_1007_s10637_024_01467_7 crossref_primary_10_1016_j_ajpath_2021_12_002 crossref_primary_10_3390_biomedicines10123283 crossref_primary_10_3389_fendo_2022_955630 crossref_primary_10_1186_s12951_022_01698_x crossref_primary_10_1002_cam4_4985 crossref_primary_10_1038_s41598_022_05987_1 crossref_primary_10_1016_j_ymthe_2021_01_019 crossref_primary_10_1016_j_ygeno_2020_12_010 crossref_primary_10_1155_2021_3062606 crossref_primary_10_1177_15353702221142607 crossref_primary_10_3389_fimmu_2024_1482746 crossref_primary_10_3390_biom11060901 crossref_primary_10_1186_s12935_020_01672_3 crossref_primary_10_3389_fgene_2023_1108167 crossref_primary_10_1007_s12094_021_02749_9 crossref_primary_10_1038_s41374_020_00512_2 crossref_primary_10_1002_cai2_125 crossref_primary_10_3389_fgene_2021_722601 crossref_primary_10_1080_19336950_2021_1965422 crossref_primary_10_3389_fonc_2021_667715 crossref_primary_10_1186_s12967_023_04575_9 crossref_primary_10_1038_s41598_024_70041_1 crossref_primary_10_1038_s41420_024_02106_z crossref_primary_10_1155_2023_1424589 crossref_primary_10_1136_jitc_2022_005660 crossref_primary_10_3389_fgene_2021_627117 crossref_primary_10_3389_fimmu_2022_921182 crossref_primary_10_1111_jop_13281 crossref_primary_10_3390_cancers11040456 crossref_primary_10_1007_s12672_024_01693_8 crossref_primary_10_1016_j_anl_2022_04_009 crossref_primary_10_1002_ctm2_478 crossref_primary_10_1038_s41598_022_09549_3 crossref_primary_10_1016_j_ijbiomac_2025_145707 crossref_primary_10_3389_fimmu_2022_907182 crossref_primary_10_1186_s12951_025_03134_2 crossref_primary_10_1016_j_ijbiomac_2023_123577 crossref_primary_10_3389_fgene_2023_1105900 crossref_primary_10_3389_pore_2023_1611016 crossref_primary_10_1097_MD_0000000000035086 crossref_primary_10_3390_cancers16142595 crossref_primary_10_7717_peerj_10142 crossref_primary_10_1097_MD_0000000000026574 crossref_primary_10_1002_cam4_2983 crossref_primary_10_3389_fgene_2022_923768 crossref_primary_10_3389_fonc_2022_971618 crossref_primary_10_3389_fcell_2024_1478478 crossref_primary_10_1016_j_prp_2025_156082 crossref_primary_10_1155_2022_3199589 crossref_primary_10_1016_j_heliyon_2024_e27022 crossref_primary_10_1016_j_jbo_2023_100481 crossref_primary_10_1111_ajco_13909 crossref_primary_10_1186_s12951_023_01771_z crossref_primary_10_3389_fgene_2023_1160915 crossref_primary_10_1002_2211_5463_13085 crossref_primary_10_1016_j_abb_2021_108838 crossref_primary_10_3389_fgene_2021_722421 crossref_primary_10_3892_etm_2021_10562 crossref_primary_10_1038_s41598_025_14621_9 crossref_primary_10_1038_s41467_021_21436_5 crossref_primary_10_1186_s12943_025_02366_y crossref_primary_10_3389_fcell_2021_803981 crossref_primary_10_1186_s13045_024_01591_0 crossref_primary_10_1016_j_actbio_2021_04_041 crossref_primary_10_1038_s41416_022_02005_z crossref_primary_10_3389_fgene_2023_1099272 crossref_primary_10_1016_j_tranon_2023_101646 crossref_primary_10_3389_fimmu_2022_960570 crossref_primary_10_2147_OTT_S447319 crossref_primary_10_3390_cancers10030061 crossref_primary_10_1016_j_colsurfb_2025_114827 crossref_primary_10_3389_fcell_2024_1389012 crossref_primary_10_1038_s41467_022_30166_1 crossref_primary_10_3390_ijms19041065 crossref_primary_10_1016_j_bcp_2025_117289 crossref_primary_10_1007_s13577_020_00380_4 crossref_primary_10_3389_fonc_2021_546455 crossref_primary_10_3389_fphar_2023_1273987 crossref_primary_10_3389_fcell_2023_1257173 crossref_primary_10_3389_fimmu_2021_613492 crossref_primary_10_1002_adma_201905823 crossref_primary_10_1007_s40588_022_00178_y crossref_primary_10_1177_10732748221121382 crossref_primary_10_1111_vde_13046 crossref_primary_10_1186_s12885_022_09722_x crossref_primary_10_1080_17425247_2025_2539959 crossref_primary_10_3389_fcimb_2023_1252905 crossref_primary_10_1016_j_heliyon_2025_e42720 crossref_primary_10_3389_fcell_2021_630355 crossref_primary_10_1002_ctm2_425 crossref_primary_10_1080_10717544_2019_1642418 crossref_primary_10_1016_j_semcancer_2022_02_015 crossref_primary_10_1186_s12935_021_01867_2 crossref_primary_10_3389_fonc_2021_639013 crossref_primary_10_1002_ptr_7755 crossref_primary_10_3389_fcell_2020_571297 crossref_primary_10_3390_biomedicines13061378 crossref_primary_10_1002_adhm_202402946 crossref_primary_10_3389_fimmu_2022_1071636 crossref_primary_10_1159_000477851 crossref_primary_10_3389_fonc_2020_579868 crossref_primary_10_1111_php_13220 crossref_primary_10_1016_j_intimp_2020_106807 crossref_primary_10_1016_j_tice_2019_07_005 crossref_primary_10_1016_j_biopha_2020_110247 crossref_primary_10_1016_j_ygeno_2023_110602 crossref_primary_10_1177_1533033820980116 crossref_primary_10_3389_fcell_2021_673295 crossref_primary_10_1002_aac2_12044 crossref_primary_10_1155_2022_3235238 crossref_primary_10_3389_fphar_2022_950831 crossref_primary_10_3389_fcell_2021_723817 crossref_primary_10_1089_dna_2019_5170 crossref_primary_10_1016_j_cdev_2023_203862 crossref_primary_10_1039_D4RA00497C crossref_primary_10_1002_mgg3_1159 crossref_primary_10_1007_s00432_020_03489_z crossref_primary_10_1038_s41598_024_65036_x crossref_primary_10_3390_genes13112120 crossref_primary_10_1002_cjp2_309 crossref_primary_10_3390_biology14030243 crossref_primary_10_1155_2022_6413783 crossref_primary_10_1016_j_ccell_2021_12_004 crossref_primary_10_1016_j_coph_2020_08_006 crossref_primary_10_3389_fimmu_2025_1568724 crossref_primary_10_1136_jitc_2024_009175 crossref_primary_10_1038_s42003_024_05765_x crossref_primary_10_3389_fphar_2024_1434137 crossref_primary_10_1210_clinem_dgaa344 crossref_primary_10_1038_s41417_024_00755_x crossref_primary_10_3389_fgene_2022_832046 crossref_primary_10_1007_s12672_025_02745_3 crossref_primary_10_1080_21655979_2021_1949838 crossref_primary_10_1186_s12967_024_05845_w crossref_primary_10_1016_j_phymed_2024_155402 crossref_primary_10_2147_IJGM_S350959 crossref_primary_10_3390_cancers14030843 crossref_primary_10_3390_cells9061450 crossref_primary_10_1016_j_biopha_2023_114410 crossref_primary_10_1016_j_semcancer_2021_09_007 crossref_primary_10_1016_j_critrevonc_2022_103592 crossref_primary_10_1111_cas_16136 crossref_primary_10_1016_j_canlet_2025_217472 crossref_primary_10_1186_s12920_023_01435_9 crossref_primary_10_1155_2023_8538240 crossref_primary_10_3390_life13010030 crossref_primary_10_1002_wsbm_1585 crossref_primary_10_3390_antiox10111801 crossref_primary_10_1016_j_jinorgbio_2024_112596 crossref_primary_10_3389_fimmu_2022_1038225 crossref_primary_10_1111_sji_13356 crossref_primary_10_1186_s12951_022_01405_w crossref_primary_10_3389_fonc_2021_802257 crossref_primary_10_1080_17425247_2022_2039621 crossref_primary_10_3389_fimmu_2023_1098847 crossref_primary_10_1002_pmic_202000103 crossref_primary_10_3389_fonc_2022_1072739 crossref_primary_10_1093_gastro_goad014 crossref_primary_10_1038_s41598_021_98966_x crossref_primary_10_1002_agt2_70080 crossref_primary_10_1016_j_ijbiomac_2022_08_111 crossref_primary_10_1002_jcb_27196 crossref_primary_10_1016_j_intimp_2023_110121 crossref_primary_10_3390_ijms22115698 crossref_primary_10_1016_j_jconrel_2023_04_010 crossref_primary_10_1155_2020_6034670 crossref_primary_10_1155_2022_7413535 crossref_primary_10_1186_s12885_021_08732_5 crossref_primary_10_3390_ijms25010423 crossref_primary_10_4103_mgr_MEDGASRES_D_24_00089 crossref_primary_10_3389_fgene_2023_996362 crossref_primary_10_3390_genes13112106 crossref_primary_10_1053_j_semdp_2023_02_003 crossref_primary_10_3389_fimmu_2024_1415148 crossref_primary_10_3390_ani14030519 crossref_primary_10_1186_s13045_023_01463_z crossref_primary_10_1016_j_mce_2022_111594 crossref_primary_10_3390_jpm12050673 crossref_primary_10_1002_adfm_202314012 crossref_primary_10_1186_s13045_023_01485_7 crossref_primary_10_3390_cancers16213581 crossref_primary_10_1111_cpr_12865 crossref_primary_10_32604_or_2023_030969 crossref_primary_10_3390_cells10082009 crossref_primary_10_3390_ijms22137239 crossref_primary_10_3390_microorganisms11020288 crossref_primary_10_1016_j_pharmthera_2019_107395 crossref_primary_10_3389_fgene_2022_822261 crossref_primary_10_1097_MD_0000000000043540 crossref_primary_10_3390_vaccines11020277 crossref_primary_10_1016_j_omto_2021_06_011 crossref_primary_10_2147_IJGM_S324432 crossref_primary_10_1038_s41420_023_01428_8 crossref_primary_10_1186_s12935_025_03755_5 crossref_primary_10_1016_j_asjsur_2023_01_032 crossref_primary_10_1155_2022_9544827 crossref_primary_10_3390_nu13020686 crossref_primary_10_1007_s11684_018_0663_7 crossref_primary_10_3390_cancers14133276 crossref_primary_10_1002_mabi_202100186 crossref_primary_10_1007_s11154_020_09567_4 crossref_primary_10_1038_s12276_022_00856_3 crossref_primary_10_1016_j_dyepig_2024_112141 crossref_primary_10_1111_jcmm_13938 crossref_primary_10_1111_sji_13177 crossref_primary_10_3390_pharmaceutics14102131 crossref_primary_10_1038_s41416_022_01886_4 crossref_primary_10_2217_imt_2022_0196 crossref_primary_10_2478_jtim_2020_0032 crossref_primary_10_1016_j_bioadv_2022_213270 crossref_primary_10_3390_cancers14051359 crossref_primary_10_3389_fcell_2021_722917 crossref_primary_10_3390_cancers12113213 crossref_primary_10_1055_s_0042_1756659 crossref_primary_10_3389_fimmu_2022_955800 crossref_primary_10_3390_cancers12102797 crossref_primary_10_1177_03000605211032807 crossref_primary_10_3390_cancers16132338 crossref_primary_10_1016_j_bbrep_2025_101950 crossref_primary_10_3389_fgene_2021_759953 crossref_primary_10_1177_15347354241247061 crossref_primary_10_1007_s12032_023_02237_w crossref_primary_10_3389_fimmu_2024_1427348 crossref_primary_10_1259_bjr_20210768 crossref_primary_10_1007_s10404_025_02827_2 crossref_primary_10_1155_2022_9141117 crossref_primary_10_3389_fonc_2021_694664 crossref_primary_10_1016_j_canlet_2019_05_017 crossref_primary_10_1016_j_molimm_2021_10_002 crossref_primary_10_1155_2022_7397250 crossref_primary_10_1016_j_bbcan_2022_188785 crossref_primary_10_1016_j_apsb_2022_12_013 crossref_primary_10_1016_j_bbcan_2025_189294 crossref_primary_10_3389_fgene_2021_743133 crossref_primary_10_3389_fonc_2021_711402 crossref_primary_10_1155_2022_1040116 crossref_primary_10_1172_JCI124919 crossref_primary_10_3389_fgene_2022_882794 crossref_primary_10_1007_s13402_021_00592_2 crossref_primary_10_1016_j_biopha_2019_109233 crossref_primary_10_1016_j_labinv_2024_102184 crossref_primary_10_1016_j_nantod_2024_102421 crossref_primary_10_1016_j_apsb_2022_11_002 crossref_primary_10_1016_j_heliyon_2024_e27207 crossref_primary_10_3389_fbioe_2022_993820 crossref_primary_10_1007_s00018_020_03539_2 crossref_primary_10_1007_s00251_021_01223_8 crossref_primary_10_1186_s12935_022_02545_7 crossref_primary_10_3389_fphar_2020_538137 crossref_primary_10_1016_j_drup_2023_101028 crossref_primary_10_3390_app15063189 crossref_primary_10_1016_j_colsurfb_2024_114398 crossref_primary_10_1053_j_seminoncol_2019_07_003 crossref_primary_10_1186_s10020_023_00726_2 crossref_primary_10_1002_adhm_201800525 crossref_primary_10_1016_j_heliyon_2024_e37217 crossref_primary_10_1016_j_ejmech_2019_111741 crossref_primary_10_1016_j_bbcan_2022_188798 crossref_primary_10_1016_j_cellsig_2023_110976 crossref_primary_10_3389_fimmu_2023_1094042 crossref_primary_10_3390_biom13020282 crossref_primary_10_3390_cancers13112795 crossref_primary_10_1016_j_celrep_2025_115510 crossref_primary_10_1038_s41420_022_01262_4 crossref_primary_10_1039_D3FO02986G crossref_primary_10_1186_s40164_024_00479_6 crossref_primary_10_1016_j_jddst_2023_104441 crossref_primary_10_3390_cells9051224 crossref_primary_10_3892_ol_2023_14011 crossref_primary_10_1093_bib_bbac034 crossref_primary_10_1155_2022_4869732 crossref_primary_10_1016_j_mtnano_2023_100430 crossref_primary_10_1155_2024_2090450 crossref_primary_10_3389_fgene_2022_1008502 crossref_primary_10_3389_fimmu_2020_621623 crossref_primary_10_1002_cbf_3462 crossref_primary_10_1016_j_matdes_2023_112251 crossref_primary_10_1111_pcmr_70040 crossref_primary_10_3390_cells10061529 crossref_primary_10_3390_ijms23169224 crossref_primary_10_15171_bi_2019_24 crossref_primary_10_3389_fimmu_2022_951455 crossref_primary_10_1016_j_bbrc_2021_01_014 crossref_primary_10_1177_0963689720977131 crossref_primary_10_1016_j_acra_2022_03_011 crossref_primary_10_1016_j_compbiomed_2024_108666 crossref_primary_10_3389_fphar_2022_965244 crossref_primary_10_3389_fonc_2023_1293441 crossref_primary_10_3390_cancers13112656 crossref_primary_10_3389_fimmu_2019_01842 crossref_primary_10_1016_j_bbrc_2019_03_136 crossref_primary_10_1016_j_bbrc_2019_11_134 crossref_primary_10_3390_ijms21103686 crossref_primary_10_3390_pharmaceutics14071344 crossref_primary_10_1016_j_heliyon_2024_e31299 crossref_primary_10_1186_s10020_021_00294_3 crossref_primary_10_3389_fimmu_2022_951247 crossref_primary_10_3389_fimmu_2025_1625208 crossref_primary_10_1016_j_mtchem_2024_102455 crossref_primary_10_1016_j_lfs_2022_121263 crossref_primary_10_3390_cancers14235808 crossref_primary_10_3389_fgene_2022_1010440 crossref_primary_10_3389_fimmu_2022_920512 crossref_primary_10_2147_JIR_S386898 crossref_primary_10_1016_j_lfs_2020_118790 crossref_primary_10_1080_14737159_2023_2219843 crossref_primary_10_1016_j_ijpharm_2025_125979 crossref_primary_10_1016_j_jbc_2021_101133 crossref_primary_10_1038_s41416_020_0895_6 crossref_primary_10_1002_adhm_202300410 crossref_primary_10_1016_j_nantod_2022_101376 crossref_primary_10_1007_s12094_024_03457_w crossref_primary_10_1080_07853890_2025_2558121 crossref_primary_10_1515_oncologie_2023_0459 crossref_primary_10_3390_nu14183790 crossref_primary_10_1016_j_lfs_2022_121270 crossref_primary_10_1007_s10142_023_01108_x crossref_primary_10_1186_s13045_020_00966_3 crossref_primary_10_1016_j_jpha_2024_101003 crossref_primary_10_3389_fendo_2023_1202493 crossref_primary_10_3389_fgene_2023_1206141 crossref_primary_10_3389_fgene_2023_1138137 crossref_primary_10_1038_s41598_024_65345_1 crossref_primary_10_1080_15384047_2024_2304161 crossref_primary_10_3390_brainsci12070927 crossref_primary_10_3389_fmed_2022_869994 crossref_primary_10_1038_s41419_025_07466_7 crossref_primary_10_1002_adhm_202401373 crossref_primary_10_3892_mmr_2023_13029 crossref_primary_10_3389_fonc_2021_769033 crossref_primary_10_1016_j_actbio_2022_09_074 crossref_primary_10_1038_s41598_024_53257_z crossref_primary_10_3390_cancers13112632 crossref_primary_10_3390_cimb46060346 crossref_primary_10_1016_j_jconrel_2019_07_016 crossref_primary_10_2147_CMAR_S346240 crossref_primary_10_32604_or_2024_048138 crossref_primary_10_1038_s41525_021_00249_x crossref_primary_10_3390_cancers15112971 crossref_primary_10_1002_slct_202301710 crossref_primary_10_3389_fimmu_2021_789914 crossref_primary_10_1126_sciadv_adv0885 crossref_primary_10_1016_j_ccr_2022_214821 crossref_primary_10_1016_j_cson_2023_100027 crossref_primary_10_1016_j_ymthe_2020_04_023 crossref_primary_10_1177_15330338211045823 crossref_primary_10_3389_fonc_2022_781686 crossref_primary_10_3389_fbioe_2020_00322 crossref_primary_10_3389_fmolb_2022_812815 crossref_primary_10_1002_adfm_202207749 crossref_primary_10_1186_s12957_022_02767_z crossref_primary_10_3390_bioengineering9110655 crossref_primary_10_1177_0963689720946653 crossref_primary_10_1002_1878_0261_13517 crossref_primary_10_3389_fphar_2022_889816 crossref_primary_10_3390_cancers13051160 crossref_primary_10_3892_ijo_2023_5572 crossref_primary_10_3389_fgene_2022_918977 crossref_primary_10_1016_j_jconrel_2025_113603 crossref_primary_10_1007_s12672_024_01534_8 crossref_primary_10_1097_MD_0000000000033664 crossref_primary_10_3389_fimmu_2022_1088886 crossref_primary_10_1177_1533033820977504 crossref_primary_10_1186_s13578_023_01071_x crossref_primary_10_1016_j_celrep_2025_115572 crossref_primary_10_3389_fgene_2024_1404348 crossref_primary_10_1007_s40820_020_00434_0 crossref_primary_10_3389_fimmu_2022_1074477 crossref_primary_10_1007_s43032_021_00600_8 crossref_primary_10_1016_j_addr_2020_05_006 crossref_primary_10_1016_j_arr_2024_102297 crossref_primary_10_1016_j_heliyon_2023_e16897 crossref_primary_10_1002_adhm_202303716 crossref_primary_10_3390_ijms241713482 crossref_primary_10_3390_cancers14184395 crossref_primary_10_4103_cjop_CJOP_D_23_00064 crossref_primary_10_1016_j_jocn_2024_04_009 crossref_primary_10_1038_s41598_024_65594_0 crossref_primary_10_3389_fphar_2023_1102277 crossref_primary_10_1016_j_phrs_2023_106987 crossref_primary_10_3389_fimmu_2021_686809 crossref_primary_10_1038_s41388_021_01853_y crossref_primary_10_1016_j_pharmthera_2022_108276 crossref_primary_10_1186_s12967_022_03423_6 crossref_primary_10_1186_s12920_023_01659_9 crossref_primary_10_3389_fcell_2021_693215 crossref_primary_10_3389_fmed_2022_950309 crossref_primary_10_1186_s12872_023_03516_0 crossref_primary_10_1016_j_canlet_2021_12_012 crossref_primary_10_3390_cells12071001 crossref_primary_10_1016_j_canlet_2019_10_020 crossref_primary_10_1371_journal_pone_0255049 crossref_primary_10_3892_or_2024_8736 crossref_primary_10_1186_s12967_020_02553_z crossref_primary_10_1016_j_bcp_2024_116366 crossref_primary_10_1016_j_cyto_2020_155311 crossref_primary_10_3390_cells14171316 crossref_primary_10_3389_fimmu_2020_612072 crossref_primary_10_1002_JLB_5A0721_396RR crossref_primary_10_3389_fimmu_2022_805552 crossref_primary_10_1007_s12094_023_03142_4 crossref_primary_10_1016_j_bioactmat_2020_12_010 crossref_primary_10_1038_s41420_021_00804_6 crossref_primary_10_3389_fphys_2023_1250982 crossref_primary_10_3389_fphar_2022_1065438 crossref_primary_10_3389_fgene_2022_1022626 crossref_primary_10_1155_2022_5244820 crossref_primary_10_1096_fj_202500124 crossref_primary_10_1097_MD_0000000000034741 crossref_primary_10_3389_fcell_2021_640957 crossref_primary_10_1088_1758_5090_acd1b8 crossref_primary_10_1002_cam4_5489 crossref_primary_10_3389_fgene_2022_926122 crossref_primary_10_3390_biom13050736 crossref_primary_10_1155_2021_7785890 crossref_primary_10_3389_fimmu_2022_1008778 crossref_primary_10_1016_j_heliyon_2023_e22083 crossref_primary_10_1155_2022_4326728 crossref_primary_10_1080_10255842_2025_2495299 crossref_primary_10_1186_s12859_022_04951_0 crossref_primary_10_3389_fimmu_2022_837590 crossref_primary_10_1097_MD_0000000000033662 crossref_primary_10_3389_fphar_2022_951480 crossref_primary_10_1002_1878_0261_12863 crossref_primary_10_1016_j_nantod_2021_101097 crossref_primary_10_1186_s12943_024_02049_0 crossref_primary_10_1007_s10142_022_00938_5 crossref_primary_10_1007_s40843_018_9261_x crossref_primary_10_1097_MD_0000000000024957 crossref_primary_10_1002_hep_32000 crossref_primary_10_1016_j_drup_2025_101290 crossref_primary_10_1080_10717544_2021_2008052 crossref_primary_10_1039_D2DT00944G crossref_primary_10_1038_s41598_021_91454_2 crossref_primary_10_3389_fonc_2020_593022 crossref_primary_10_1016_j_surg_2024_108965 crossref_primary_10_1038_s41598_020_76048_8 crossref_primary_10_1002_cti2_1522 crossref_primary_10_1177_15330338211045213 crossref_primary_10_3390_cancers14184522 crossref_primary_10_3892_etm_2023_12285 crossref_primary_10_1016_j_cellsig_2024_111041 crossref_primary_10_1111_cas_15610 crossref_primary_10_3390_cancers17162684 crossref_primary_10_1186_s12957_022_02641_y crossref_primary_10_3390_cancers15143622 crossref_primary_10_1016_j_lfs_2024_123184 crossref_primary_10_1097_MD_0000000000034164 crossref_primary_10_1186_s12943_021_01463_y crossref_primary_10_1186_s13005_024_00466_6 crossref_primary_10_3389_fonc_2023_1228185 crossref_primary_10_1038_s41598_020_72886_8 crossref_primary_10_3389_fgene_2021_771062 crossref_primary_10_1016_j_cellsig_2020_109886 crossref_primary_10_3389_fimmu_2023_1199513 crossref_primary_10_1007_s10555_023_10119_w crossref_primary_10_1038_s41416_021_01456_0 crossref_primary_10_1002_adma_202300934 crossref_primary_10_3389_fmed_2023_1257898 crossref_primary_10_1016_j_canlet_2021_12_023 crossref_primary_10_1038_s41598_024_84916_w crossref_primary_10_1016_j_cellsig_2024_111034 crossref_primary_10_3389_fneur_2022_832944 crossref_primary_10_1186_s13046_020_01688_7 crossref_primary_10_3390_ijms21165747 crossref_primary_10_1002_adma_202310964 crossref_primary_10_1186_s12967_022_03510_8 crossref_primary_10_1111_his_15093 crossref_primary_10_1080_10717544_2022_2069877 crossref_primary_10_1016_j_bbcan_2024_189158 crossref_primary_10_1038_s41598_018_37273_4 crossref_primary_10_1186_s12943_024_02165_x crossref_primary_10_1016_j_heliyon_2023_e23522 crossref_primary_10_1177_11769351221090921 crossref_primary_10_3389_fmolb_2020_598221 crossref_primary_10_1016_j_phrs_2022_106456 crossref_primary_10_1016_j_csbj_2023_04_015 crossref_primary_10_3389_fimmu_2022_992611 crossref_primary_10_3390_jpm12091521 crossref_primary_10_1007_s12672_024_01505_z crossref_primary_10_1002_elps_202100360 crossref_primary_10_1038_s41568_020_00308_y crossref_primary_10_1007_s00432_022_04253_1 crossref_primary_10_2174_1381612829666230413094242 crossref_primary_10_3389_fimmu_2023_1045024 crossref_primary_10_1002_advs_202207357 crossref_primary_10_1096_fj_202302176R crossref_primary_10_2147_PGPM_S382564 crossref_primary_10_1186_s13045_022_01340_1 crossref_primary_10_1097_MD_0000000000040820 crossref_primary_10_3390_cancers13184552 crossref_primary_10_1186_s12905_023_02420_1 crossref_primary_10_1186_s12967_024_05709_3 crossref_primary_10_3389_fphar_2025_1546491 crossref_primary_10_3389_fcell_2021_651406 crossref_primary_10_3390_cells10020416 crossref_primary_10_3389_fonc_2021_678333 crossref_primary_10_3390_biom10121695 crossref_primary_10_1038_s41416_023_02500_x crossref_primary_10_3389_fonc_2020_01546 crossref_primary_10_1515_med_2023_0715 crossref_primary_10_3390_cancers14092337 crossref_primary_10_1007_s12032_024_02370_0 crossref_primary_10_1038_s41401_022_00873_y crossref_primary_10_3389_fmolb_2023_1202524 crossref_primary_10_3389_fmolb_2022_807497 crossref_primary_10_1016_j_clim_2022_109073 crossref_primary_10_1155_2021_9250207 crossref_primary_10_1002_jcb_29633 crossref_primary_10_3892_ol_2021_12869 crossref_primary_10_1016_j_compbiomed_2023_106831 crossref_primary_10_1155_2018_2389523 crossref_primary_10_3389_fimmu_2023_1222425 crossref_primary_10_3389_fimmu_2024_1435651 crossref_primary_10_3389_fonc_2020_01770 crossref_primary_10_1016_j_apmt_2023_102047 crossref_primary_10_1016_j_intimp_2021_108346 crossref_primary_10_1016_j_ejps_2018_03_015 crossref_primary_10_3389_fonc_2020_01532 crossref_primary_10_1002_cac2_12078 crossref_primary_10_3389_fimmu_2022_888713 crossref_primary_10_1002_bies_202000272 crossref_primary_10_3390_cancers12071748 crossref_primary_10_1186_s13048_020_00763_z crossref_primary_10_1248_bpb_b25_00258 crossref_primary_10_3389_fonc_2025_1547067 crossref_primary_10_1016_j_tranon_2020_100972 crossref_primary_10_3892_ijo_2022_5374 crossref_primary_10_1186_s12885_021_08350_1 crossref_primary_10_1111_and_13986 crossref_primary_10_1007_s12264_023_01126_6 crossref_primary_10_1080_02648725_2023_2217611 crossref_primary_10_1007_s13139_025_00935_z crossref_primary_10_1186_s12935_021_01830_1 crossref_primary_10_1177_15330338251374945 crossref_primary_10_3389_fgene_2022_969476 crossref_primary_10_3390_genes13050787 crossref_primary_10_1155_2022_4320809 crossref_primary_10_3390_cancers12071755 crossref_primary_10_2174_0115748928258157231128103337 crossref_primary_10_1002_cam4_4302 crossref_primary_10_3892_mmr_2021_12552 crossref_primary_10_1158_2326_6066_CIR_20_0645 crossref_primary_10_1093_carcin_bgaa128 crossref_primary_10_3389_fonc_2020_01511 crossref_primary_10_3389_fonc_2021_679851 crossref_primary_10_1002_ctd2_202 crossref_primary_10_1039_D1BM00531F crossref_primary_10_3389_fimmu_2025_1554835 crossref_primary_10_3390_ijms241713413 crossref_primary_10_1016_j_cytogfr_2022_07_006 crossref_primary_10_1186_s13099_025_00729_w crossref_primary_10_3389_fimmu_2021_646523 crossref_primary_10_3390_cancers13050954 crossref_primary_10_3389_fimmu_2022_871076 crossref_primary_10_3389_fonc_2023_1180191 crossref_primary_10_3389_fgene_2022_1037716 crossref_primary_10_1007_s00259_025_07084_7 crossref_primary_10_1080_1120009X_2021_2011661 crossref_primary_10_1186_s13046_020_1536_x crossref_primary_10_2147_IJGM_S351662 crossref_primary_10_3389_fbioe_2021_682498 crossref_primary_10_3389_fnano_2025_1587439 crossref_primary_10_3390_cells11223626 crossref_primary_10_1016_j_carpta_2025_100952 crossref_primary_10_1016_j_intimp_2025_114546 crossref_primary_10_1016_j_jconrel_2024_08_047 crossref_primary_10_1186_s13045_021_01134_x crossref_primary_10_3389_fimmu_2022_901784 crossref_primary_10_3389_fimmu_2022_1046121 crossref_primary_10_1007_s12672_025_02622_z crossref_primary_10_1097_MD_0000000000030758 crossref_primary_10_1002_mp_14767 crossref_primary_10_1016_j_curtheres_2024_100760 crossref_primary_10_1080_17520363_2024_2385297 crossref_primary_10_3389_fgene_2021_721419 crossref_primary_10_3389_fonc_2023_1134063 crossref_primary_10_3389_fonc_2025_1508173 crossref_primary_10_3389_fgene_2021_687778 crossref_primary_10_1016_j_pbiomolbio_2025_01_001 crossref_primary_10_3389_fcell_2022_818194 crossref_primary_10_1038_s41598_025_04440_3 crossref_primary_10_3389_fphar_2023_1088993 crossref_primary_10_3390_pharmaceutics12121186 crossref_primary_10_3390_jpm11101031 crossref_primary_10_1002_admi_202001055 crossref_primary_10_1016_j_ijbiomac_2022_09_201 crossref_primary_10_1097_MD_0000000000027332 crossref_primary_10_3390_cancers12102870 crossref_primary_10_2147_DDDT_S308973 crossref_primary_10_3390_pharmaceutics15071788 crossref_primary_10_1042_BSR20202439 crossref_primary_10_1007_s12031_023_02120_3 crossref_primary_10_1002_VIW_20200129 crossref_primary_10_1002_jcla_24141 crossref_primary_10_1002_adhm_202202787 crossref_primary_10_1016_j_bbcan_2020_188461 crossref_primary_10_3389_fimmu_2025_1604179 crossref_primary_10_1038_s41420_021_00647_1 crossref_primary_10_1186_s12906_022_03660_8 crossref_primary_10_1155_2022_6568278 crossref_primary_10_3390_ijms26146629 crossref_primary_10_1016_j_apsb_2024_05_010 crossref_primary_10_1016_j_canlet_2021_10_045 crossref_primary_10_1038_s41420_024_01982_9 crossref_primary_10_3389_fcell_2021_767253 crossref_primary_10_3390_cancers15010113 crossref_primary_10_1111_jdv_17437 crossref_primary_10_1111_jcmm_17517 crossref_primary_10_3389_fimmu_2024_1295693 crossref_primary_10_1158_1541_7786_MCR_21_0526 crossref_primary_10_1016_j_ijpharm_2023_123316 crossref_primary_10_1002_tox_23821 crossref_primary_10_3389_fimmu_2022_923477 crossref_primary_10_3389_fimmu_2022_985911 crossref_primary_10_1038_s41419_023_06108_0 crossref_primary_10_3389_fendo_2023_1131525 crossref_primary_10_3390_biom12121835 crossref_primary_10_3390_cancers15020394 crossref_primary_10_1016_j_jbiosc_2024_01_002 crossref_primary_10_3389_fcimb_2024_1411249 crossref_primary_10_3389_fcell_2021_657917 crossref_primary_10_1016_j_bbcan_2020_188434 crossref_primary_10_1016_j_ejmech_2022_114898 crossref_primary_10_2147_IJN_S254774 crossref_primary_10_1016_j_heliyon_2024_e39564 crossref_primary_10_1007_s00109_021_02138_3 crossref_primary_10_1038_s41698_025_00883_z crossref_primary_10_1002_cam4_5721 crossref_primary_10_1097_MD_0000000000032927 crossref_primary_10_1155_jimr_4341348 crossref_primary_10_1016_j_addr_2021_04_018 crossref_primary_10_3389_fphar_2021_748867 crossref_primary_10_1016_j_bbamcr_2020_118644 crossref_primary_10_3389_fimmu_2021_688961 crossref_primary_10_1016_j_intimp_2024_112053 crossref_primary_10_3389_fonc_2021_753386 crossref_primary_10_1002_adtp_202100196 crossref_primary_10_4103_jcrt_jcrt_749_23 crossref_primary_10_3389_fimmu_2024_1501659 crossref_primary_10_1155_2022_8213321 crossref_primary_10_3390_cancers13071676 crossref_primary_10_1016_j_mtbio_2025_101626 crossref_primary_10_1002_adhm_202000912 crossref_primary_10_3390_ph14020133 crossref_primary_10_1038_s41416_022_02090_0 crossref_primary_10_3390_biom12121860 crossref_primary_10_3390_biom15030326 crossref_primary_10_3390_cancers14143335 crossref_primary_10_1007_s12072_023_10593_y crossref_primary_10_1016_j_intimp_2025_114105 crossref_primary_10_7759_cureus_82869 crossref_primary_10_3389_fonc_2021_709865 crossref_primary_10_1002_advs_202002518 crossref_primary_10_1016_j_canlet_2024_216842 crossref_primary_10_1177_15353702231215897 crossref_primary_10_1016_j_ctarc_2020_100297 crossref_primary_10_1155_2023_1904309 crossref_primary_10_1002_mog2_70012 crossref_primary_10_1080_21655979_2021_1955511 crossref_primary_10_1186_s12885_022_09366_x crossref_primary_10_3390_cancers15020376 crossref_primary_10_3390_pharmaceutics16030346 crossref_primary_10_3390_pharmaceutics16030345 crossref_primary_10_1007_s12274_022_4542_9 crossref_primary_10_1088_1748_605X_acd830 crossref_primary_10_1186_s12883_021_02477_1 crossref_primary_10_1007_s13577_023_00886_7 crossref_primary_10_1016_j_yexcr_2022_113277 crossref_primary_10_32604_biocell_2023_028336 crossref_primary_10_2147_IJN_S312823 crossref_primary_10_1016_j_ccr_2023_215632 crossref_primary_10_3389_fphar_2024_1502349 crossref_primary_10_3389_fimmu_2024_1494887 crossref_primary_10_1634_theoncologist_2017_0538 crossref_primary_10_1186_s12885_021_07996_1 crossref_primary_10_3389_fimmu_2023_1129465 crossref_primary_10_1016_j_tranon_2023_101768 crossref_primary_10_1093_bfgp_elad056 crossref_primary_10_1186_s12935_019_0957_0 crossref_primary_10_1177_20587384211018389 crossref_primary_10_1016_j_apsb_2022_02_008 crossref_primary_10_1038_s41598_025_05997_9 crossref_primary_10_3390_cimb46090588 crossref_primary_10_1007_s12672_025_02078_1 crossref_primary_10_1042_BSR20210040 crossref_primary_10_1016_j_biopha_2024_116657 crossref_primary_10_1155_2022_3152114 crossref_primary_10_2147_IJN_S243223 crossref_primary_10_1007_s12672_025_01767_1 crossref_primary_10_3389_fcell_2021_733270 crossref_primary_10_1016_j_yexcr_2020_111942 crossref_primary_10_3389_fgene_2022_877278 crossref_primary_10_3389_fgene_2022_983445 crossref_primary_10_3389_fimmu_2022_913951 crossref_primary_10_3389_fmolb_2022_910928 crossref_primary_10_3389_fimmu_2022_1003419 crossref_primary_10_1007_s10528_023_10446_1 crossref_primary_10_3389_fgene_2022_948920 crossref_primary_10_1038_s41598_025_10669_9 crossref_primary_10_3389_fonc_2023_1146477 crossref_primary_10_3389_fimmu_2020_02046 crossref_primary_10_1016_j_nano_2020_102240 crossref_primary_10_1155_2022_9514697 crossref_primary_10_1016_j_biopha_2024_116624 crossref_primary_10_1002_ijc_34471 crossref_primary_10_3389_fgene_2023_1097179 crossref_primary_10_1016_j_heliyon_2024_e31877 crossref_primary_10_1016_j_pdpdt_2020_101746 crossref_primary_10_3389_fimmu_2022_874056 crossref_primary_10_3389_fphar_2023_1130399 crossref_primary_10_3389_fphar_2024_1344317 crossref_primary_10_1002_ptr_6784 crossref_primary_10_1063_5_0206058 crossref_primary_10_1089_omi_2021_0221 crossref_primary_10_1186_s13073_020_00741_6 crossref_primary_10_3389_fimmu_2023_1175343 crossref_primary_10_1039_D0NR03726E crossref_primary_10_1038_s41388_025_03359_3 crossref_primary_10_1080_2162402X_2018_1498437 crossref_primary_10_1016_j_biomaterials_2022_121688 crossref_primary_10_3389_fcell_2021_705280 crossref_primary_10_1016_j_trac_2020_116118 crossref_primary_10_3390_cancers15061892 crossref_primary_10_3390_cancers15123147 crossref_primary_10_1016_j_yexcr_2019_111568 crossref_primary_10_1186_s12876_021_02073_0 crossref_primary_10_1016_j_jep_2023_117013 crossref_primary_10_3389_fimmu_2022_994259 crossref_primary_10_3389_fimmu_2020_00922 crossref_primary_10_3390_biomedicines10030708 crossref_primary_10_1002_JLB_2BT1018_715RR crossref_primary_10_3390_cells9092061 crossref_primary_10_1016_j_tranon_2022_101452 crossref_primary_10_3389_fendo_2023_1137456 crossref_primary_10_1186_s12964_024_01570_5 crossref_primary_10_3389_fphar_2022_949713 crossref_primary_10_1016_j_molimm_2025_08_005 crossref_primary_10_1186_s12943_023_01761_7 crossref_primary_10_2147_OTT_S315998 crossref_primary_10_1007_s12033_023_00754_7 crossref_primary_10_1155_2020_6472153 crossref_primary_10_1111_jcmm_18478 crossref_primary_10_1186_s12951_022_01250_x crossref_primary_10_1007_s12094_022_03010_7 crossref_primary_10_1016_j_nantod_2025_102805 crossref_primary_10_3389_fimmu_2025_1538635 crossref_primary_10_1016_j_medj_2024_08_010 crossref_primary_10_1155_2022_5563668 crossref_primary_10_3390_cancers16030598 crossref_primary_10_3389_fonc_2021_752444 crossref_primary_10_3389_fonc_2020_00920 crossref_primary_10_3389_fimmu_2020_595207 crossref_primary_10_3389_fphar_2021_702445 crossref_primary_10_1002_1878_0261_13384 crossref_primary_10_2147_IJGM_S388537 crossref_primary_10_3389_fonc_2024_1421067 crossref_primary_10_1007_s12032_025_02737_x crossref_primary_10_1016_j_jinorgbio_2022_111815 crossref_primary_10_3389_fendo_2022_1031210 crossref_primary_10_3389_fimmu_2023_1171883 crossref_primary_10_3389_fonc_2020_557157 crossref_primary_10_1016_j_canlet_2019_10_016 crossref_primary_10_1039_D3QM01308A crossref_primary_10_1007_s00280_021_04378_z crossref_primary_10_3892_or_2023_8486 crossref_primary_10_1016_j_bbrc_2024_149983 crossref_primary_10_1038_s41388_025_03435_8 crossref_primary_10_3389_fgene_2023_1218408 crossref_primary_10_3389_fimmu_2022_890150 crossref_primary_10_1016_j_cca_2022_06_009 crossref_primary_10_3390_cancers13061243 crossref_primary_10_1038_s41392_023_01683_2 crossref_primary_10_1049_nbt2_12128 crossref_primary_10_1016_j_lfs_2021_120166 crossref_primary_10_1002_mco2_70078 crossref_primary_10_3389_fgene_2021_733211 crossref_primary_10_1186_s13046_023_02729_7 crossref_primary_10_3389_fimmu_2022_872991 crossref_primary_10_1016_j_copbio_2024_103111 crossref_primary_10_1186_s13578_023_01073_9 crossref_primary_10_2174_1574893617666220408085955 crossref_primary_10_2147_OTT_S301371 crossref_primary_10_1007_s10238_024_01534_6 crossref_primary_10_1097_MD_0000000000039153 crossref_primary_10_1093_hmg_ddad204 crossref_primary_10_1097_JP9_0000000000000147 crossref_primary_10_1038_s41570_025_00749_9 crossref_primary_10_3390_cancers17182963 crossref_primary_10_1007_s00259_025_07321_z crossref_primary_10_1155_2022_9109365 crossref_primary_10_1007_s40279_024_02031_2 crossref_primary_10_1111_jcmm_17127 crossref_primary_10_1155_2022_4085770 crossref_primary_10_32604_or_2022_03554 crossref_primary_10_3389_fmolb_2022_884839 crossref_primary_10_3390_ijms22020791 crossref_primary_10_3389_fonc_2021_710695 crossref_primary_10_1016_j_cej_2024_148522 crossref_primary_10_1155_2022_8933167 crossref_primary_10_1038_s41598_020_68074_3 crossref_primary_10_1158_0008_5472_CAN_20_3471 crossref_primary_10_3389_fimmu_2022_1051998 crossref_primary_10_2147_IJGM_S341076 crossref_primary_10_3389_fonc_2022_984896 crossref_primary_10_3390_cancers13030558 crossref_primary_10_1016_j_bioorg_2021_104891 crossref_primary_10_3390_ijms21239287 crossref_primary_10_1002_adfm_202002753 crossref_primary_10_1080_21655979_2021_1936831 crossref_primary_10_2147_IJN_S401038 crossref_primary_10_1007_s12672_025_03012_1 crossref_primary_10_3389_fgene_2021_654657 crossref_primary_10_1016_j_bbrc_2016_05_064 crossref_primary_10_1016_j_ejmech_2022_114439 crossref_primary_10_1088_1748_605X_ab9bb2 crossref_primary_10_2147_DDDT_S375073 crossref_primary_10_3390_biomedicines11030709 crossref_primary_10_3389_fonc_2022_929655 crossref_primary_10_1007_s00432_023_04881_1 crossref_primary_10_1038_s41598_023_48374_0 crossref_primary_10_3389_fvets_2020_598338 crossref_primary_10_3389_fonc_2022_877147 crossref_primary_10_1016_j_carbpol_2023_120997 crossref_primary_10_1002_advs_202203973 crossref_primary_10_1002_adhm_202002036 crossref_primary_10_1016_j_ejphar_2024_176727 crossref_primary_10_1038_s41467_022_31719_0 crossref_primary_10_1038_s41598_022_27316_2 crossref_primary_10_1039_D3NH00388D crossref_primary_10_1038_s41375_024_02217_7 crossref_primary_10_3389_fonc_2022_888276 crossref_primary_10_1016_j_drup_2019_100647 crossref_primary_10_1016_j_intimp_2020_106795 crossref_primary_10_1186_s12929_023_00903_9 crossref_primary_10_1186_s12957_023_03013_w crossref_primary_10_3389_fmolb_2021_763902 crossref_primary_10_3390_ijms23158231 crossref_primary_10_1016_j_biopha_2025_118045 crossref_primary_10_1016_j_intimp_2024_111854 crossref_primary_10_1038_s41598_024_69183_z crossref_primary_10_3389_fgene_2022_877086 crossref_primary_10_3390_ijms232113470 crossref_primary_10_3389_fcell_2021_746194 crossref_primary_10_1016_j_nantod_2025_102864 crossref_primary_10_1038_s41420_021_00556_3 crossref_primary_10_3389_fonc_2023_1164266 crossref_primary_10_1007_s00210_025_04390_7 crossref_primary_10_3390_cells12202510 crossref_primary_10_1038_s41598_023_42985_3 crossref_primary_10_1245_s10434_022_12058_2 crossref_primary_10_3389_fgene_2022_1028469 crossref_primary_10_1007_s00432_023_05042_0 crossref_primary_10_1155_2022_6602648 crossref_primary_10_3390_molecules26123494 crossref_primary_10_3389_fonc_2022_964838 crossref_primary_10_1016_j_ab_2022_114567 crossref_primary_10_3390_cells11213432 crossref_primary_10_1111_cns_14599 crossref_primary_10_1186_s12951_023_01850_1 crossref_primary_10_3389_fimmu_2024_1408700 crossref_primary_10_1002_smsc_202400084 crossref_primary_10_1016_j_cclet_2020_05_027 crossref_primary_10_3748_wjg_v26_i8_789 crossref_primary_10_3389_fcell_2021_657547 crossref_primary_10_3389_fonc_2022_970279 crossref_primary_10_1186_s12957_021_02299_y crossref_primary_10_3390_pharmaceutics14091763 crossref_primary_10_4103_jcrt_jcrt_2670_22 crossref_primary_10_3389_fnano_2021_753766 crossref_primary_10_1002_1878_0261_13319 crossref_primary_10_3389_fimmu_2022_947080 crossref_primary_10_2174_0109298673268718231122103638 |
| Cites_doi | 10.2353/ajpath.2009.090202 10.1038/nm.2999 10.1016/S1470-2045(15)00132-1 10.1038/35094059 10.1016/j.intimp.2011.01.030 10.1182/blood-2011-10-383406 10.1182/blood-2009-08-237412 10.1158/0008-5472.CAN-05-3387 10.1189/jlb.71.3.495 10.1016/j.cell.2010.03.014 10.1016/S0092-8674(00)81731-6 10.1016/j.cell.2005.02.034 10.1182/blood-2008-05-158311 10.1038/nri3902 10.1038/nm909 10.1038/nrc1877 10.1007/s10637-012-9869-8 10.1182/blood.V95.8.2630 10.1146/annurev-immunol-032712-100008 10.1101/gad.180331.111 10.1007/s00262-009-0747-y 10.1158/0008-5472.CAN-05-3523 10.1016/j.ajpath.2011.11.029 10.1038/cdd.2013.67 10.1016/j.semcancer.2008.03.004 10.1038/onc.2013.357 10.1016/j.ccr.2012.02.017 10.1126/scitranslmed.3007974 10.1182/blood.V88.2.667.bloodjournal882667 10.1016/j.ccr.2014.05.016 10.1016/j.ccell.2014.09.006 10.1002/ijc.24401 10.1111/j.1365-2141.2011.08864.x 10.18632/oncotarget.3099 10.1158/0008-5472.CAN-11-2449 10.1007/s10549-009-0502-2 10.1038/sj.bjc.6603176 10.1007/s00262-003-0459-7 10.1038/nrc3581 10.1038/nm.3394 10.1084/jem.20080108 10.1172/JCI26532 10.1182/blood-2004-12-4918 10.1097/JTO.0b013e3181a97e31 10.1172/JCI66553 10.4049/jimmunol.159.5.2212 10.1158/0008-5472.CAN-05-3077 10.1007/s11060-014-1365-x 10.1002/eji.201242505 10.1007/s00280-013-2099-8 10.1016/j.humimm.2009.01.014 10.1182/blood-2012-01-406272 10.1016/j.bbrc.2013.06.089 10.1016/j.immuni.2013.07.017 10.1007/s10637-012-9857-z 10.1073/pnas.1106645108 10.1038/nature06348 10.1074/jbc.M110.168617 10.1002/path.4133 10.1016/j.tcb.2014.11.006 10.1158/1078-0432.CCR-13-1320 10.1073/pnas.0902280106 10.1002/eji.200324270 10.1016/j.cell.2011.02.013 10.1093/jnci/djm135 10.1593/neo.11324 10.1016/j.ygyno.2013.12.031 10.1016/j.molonc.2014.03.016 10.1530/JOE-10-0377 10.1002/eji.201142335 10.1016/j.cell.2012.04.042 10.1158/0008-5472.CAN-07-6390 10.1007/s10637-010-9573-5 10.1182/blood-2002-09-2907 10.1038/nm.3560 10.1007/s11523-014-0320-2 10.1016/j.it.2015.02.004 10.1182/blood-2004-03-0889 10.1038/nature11183 10.1016/S1470-2045(14)70379-1 10.4161/cc.8.10.8557 10.1038/sj.cdd.4401849 10.1038/nm.3291 10.1093/neuonc/not082 10.1084/jem.20061104 10.1084/jem.20150295 10.1158/2159-8274.CD-10-0028 10.1158/0008-5472.CAN-07-2593 10.1073/pnas.94.5.1785 10.1016/j.ccr.2012.04.025 10.1016/j.yexcr.2010.04.032 10.1111/j.1365-2141.1994.tb05017.x 10.1038/sj.leu.2400556 10.1158/0008-5472.CAN-06-4639 10.1182/blood.V98.2.428 10.1002/cncr.24821 10.1158/1078-0432.CCR-09-3272 10.1084/jem.176.5.1319 10.1182/blood.V99.11.4138 10.1038/onc.2010.350 10.1038/nri3175 10.1016/j.bcp.2013.01.018 10.1016/S1535-6108(03)00058-8 10.1158/0008-5472.CAN-10-3055 10.1016/j.ccr.2012.02.022 10.1074/jbc.C300173200 10.1038/nbt1323 10.1038/nm.3337 10.1016/j.cell.2013.12.041 10.1158/1078-0432.CCR-08-1612 10.1126/science.1198443 10.1007/s00262-013-1396-8 10.1038/sj.onc.1204554 10.18632/oncotarget.1893 10.1038/nrc2714 10.1097/JTO.0000000000000193 10.1158/0008-5472.CAN-12-3542 10.1182/blood.V96.8.2655 |
| ContentType | Journal Article |
| Copyright | 2016 Elsevier Ireland Ltd Elsevier Ireland Ltd Copyright © 2016 Elsevier Ireland Ltd. All rights reserved. Copyright Elsevier Limited Feb 28, 2017 |
| Copyright_xml | – notice: 2016 Elsevier Ireland Ltd – notice: Elsevier Ireland Ltd – notice: Copyright © 2016 Elsevier Ireland Ltd. All rights reserved. – notice: Copyright Elsevier Limited Feb 28, 2017 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TO 7U9 H94 K9. NAPCQ 7U8 7X8 C1K JXQ |
| DOI | 10.1016/j.canlet.2016.01.043 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium TOXLINE MEDLINE - Academic Environmental Sciences and Pollution Management Toxline |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts TOXLINE MEDLINE - Academic Environmental Sciences and Pollution Management |
| DatabaseTitleList | Oncogenes and Growth Factors Abstracts MEDLINE TOXLINE AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1872-7980 |
| EndPage | 68 |
| ExternalDocumentID | 4293345291 26845449 10_1016_j_canlet_2016_01_043 S0304383516300155 1_s2_0_S0304383516300155 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29B 4.4 457 4CK 4G. 5GY 5RE 5VS 6J9 6PF 7-5 71M 8FE 8FH 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABGSF ABJNI ABMAC ABMZM ABUDA ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT ADUVX AEBSH AEFWE AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFPUW AFRAH AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AHMBA AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IH2 IHE J1W K-O KOM LK8 M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 ROL RPZ SCC SDF SDG SDP SEL SES SPCBC SSH SSU SSZ T5K Z5R ~G- ~HD .55 .GJ 3O- 3V. 53G 7RV 7X7 8C1 8FI AACTN AAQXK ABWVN ABXDB ACRPL ADMUD ADNMO AFCTW AFFNX AFJKZ AFKRA AFKWA AGRDE AI. AJOXV AMFUW ASPBG AVWKF AZFZN AZQEC BBNVY BENPR BHPHI FEDTE FGOYB FYUFA G-2 GUQSH HCIFZ HED HMK HMO HVGLF HZ~ M1P M2M M2O M7P R2- RIG SAE SEW UDS VH1 WUQ X7M ZGI AAIAV ABLVK ABYKQ AJBFU DOVZS LCYCR 9DU AAYXX AGQPQ AIGII CITATION CGR CUY CVF ECM EIF NPM 7TO 7U9 H94 K9. NAPCQ 7U8 7X8 C1K JXQ |
| ID | FETCH-LOGICAL-c601t-3fc1f39f5f6d3c569ca9da120eaf784aa7876fba5330cc8ab0a407ea3e5b2c303 |
| ISICitedReferencesCount | 1449 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000393256100008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0304-3835 |
| IngestDate | Sun Sep 28 14:02:22 EDT 2025 Sun Sep 28 05:45:01 EDT 2025 Tue Oct 07 06:38:11 EDT 2025 Wed Feb 19 02:40:28 EST 2025 Tue Nov 18 21:57:31 EST 2025 Sat Nov 29 03:45:25 EST 2025 Fri Feb 23 02:33:50 EST 2024 Tue Feb 25 20:11:25 EST 2025 Tue Oct 14 19:27:40 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | SFM-DR CLL TNFα CSF1 Target therapy CXCL1/2 CXCR4 Microenvironment CAFs PI3K TAMs GM-CSF CCL2 SDF1 AML CAM-DR IFNγ MM EM-DR FGF HGF TECs TKIs VEGF MMPs PKC IGF1 MAPK TME bFGF ECM Resistance MDSCs ERK1/2 TGF PDGF ATRA FGFR3 basic fibroblast growth factor platelet-derived growth factor chemokine (C-X-C motif) ligand 1/2 stromal cell-derived factor 1 tumor-associated macrophages fibroblast growth factor colony-stimulating factor 1 matrix metalloproteinases all-trans retinoic acid multiple myeloma cancer-associated fibroblasts soluble factor-mediated drug resistance phosphoinositol 3 kinase granulocyte-macrophage colony-stimulating factor insulin-like growth factor 1 environment-mediated drug resistance tumor necrosis factor α fibroblast growth factor receptor 3 cell adhesion-mediated drug resistance mitogen-activated protein kinase tyrosine kinase inhibitors acute myeloid leukemia chemokine (C-C motif) ligand 2 hepatocyte growth factor interferon γ extracellular signal-regulated kinase 1/2 protein kinase C tumor-associated endothelial cells myeloid-derived suppressor cells chronic lymphocytic leukemia chemokine (C-X-C motif) receptor 4 vascular endothelial growth factor tumor microenvironment transforming growth factor extracellular matrix |
| Language | English |
| License | Copyright © 2016 Elsevier Ireland Ltd. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c601t-3fc1f39f5f6d3c569ca9da120eaf784aa7876fba5330cc8ab0a407ea3e5b2c303 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| PMID | 26845449 |
| PQID | 1855306645 |
| PQPubID | 2031080 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1859486090 proquest_miscellaneous_1826658935 proquest_journals_1855306645 pubmed_primary_26845449 crossref_citationtrail_10_1016_j_canlet_2016_01_043 crossref_primary_10_1016_j_canlet_2016_01_043 elsevier_sciencedirect_doi_10_1016_j_canlet_2016_01_043 elsevier_clinicalkeyesjournals_1_s2_0_S0304383516300155 elsevier_clinicalkey_doi_10_1016_j_canlet_2016_01_043 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-02-28 |
| PublicationDateYYYYMMDD | 2017-02-28 |
| PublicationDate_xml | – month: 02 year: 2017 text: 2017-02-28 day: 28 |
| PublicationDecade | 2010 |
| PublicationPlace | Ireland |
| PublicationPlace_xml | – name: Ireland – name: Clare |
| PublicationTitle | Cancer letters |
| PublicationTitleAlternate | Cancer Lett |
| PublicationYear | 2017 |
| Publisher | Elsevier B.V Elsevier Limited |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier Limited |
| References | Sherman-Baust, Weeraratna, Rangel, Pizer, Cho, Schwartz (bib0330) 2003; 3 Matsunaga, Takemoto, Sato, Takimoto, Tanaka, Fujimi (bib0305) 2003; 9 Shree, Olson, Elie, Kester, Garfall, Simpson (bib0135) 2011; 25 Bruchard, Mignot, Derangere, Chalmin, Chevriaux, Vegran (bib0395) 2013; 19 Kim, Turnbull, Guimond (bib0210) 2011; 209 Shojaei, Wu, Malik, Zhong, Baldwin, Schanz (bib0130) 2007; 25 Jewell, Worman, Lydyard, Yong, Giles, Goldstone (bib0275) 1994; 88 Talmadge, Gabrilovich (bib0185) 2013; 13 Nishio, Endo, Tsukada, Ohata, Kitada, Reed (bib0240) 2005; 106 Podar, Zimmerhackl, Fulciniti, Tonon, Hainz, Tai (bib0445) 2011; 155 Orimo, Gupta, Sgroi, Arenzana-Seisdedos, Delaunay, Naeem (bib0050) 2005; 121 Fujita, Kohanbash, Fellows-Mayle, Hamilton, Komohara, Decker (bib0555) 2011; 71 Misra, Ghatak, Zoltan-Jones, Toole (bib0340) 2003; 278 Burger, Tsukada, Burger, Zvaifler, Dell'Aquila, Kipps (bib0235) 2000; 96 Akino, Hida, Hida, Tsuchiya, Freedman, Muraki (bib0160) 2009; 175 Lathers, Clark, Achille, Young (bib0575) 2004; 53 Griffioen, Damen, Blijham, Groenewegen (bib0180) 1996; 88 Bayne, Beatty, Jhala, Clark, Rhim, Stanger (bib0525) 2012; 21 Lin, Podar, Gupta, Tai, Li, Weller (bib0415) 2002; 62 Qian, Pollard (bib0080) 2010; 141 Nakasone, Askautrud, Kees, Park, Plaks, Ewald (bib0355) 2012; 21 Alva, Slovin, Daignault, Carducci, Dipaola, Pienta (bib0460) 2012; 30 Bisping, Leo, Wenning, Dankbar, Padro, Kropff (bib0290) 2003; 101 Weizman, Krelin, Shabtay-Orbach, Amit, Binenbaum, Wong (bib0370) 2014; 33 Eisele, Wick, Eisele, Clement, Tonn, Tabatabai (bib0465) 2014; 117 Konig, Menzel, Lynen, Wrazel, Rosen, Al-Katib (bib0280) 1997; 11 Obermajer, Muthuswamy, Odunsi, Edwards, Kalinski (bib0545) 2011; 71 Bracci, Schiavoni, Sistigu, Belardelli (bib0595) 2014; 21 Margolin, Silinsky, Grimes, Spencer, Aycock, Green (bib0250) 2011; 13 Hudes, Tagawa, Whang, Qi, Qin, Puchalski (bib0430) 2013; 31 Hanahan, Coussens (bib0010) 2012; 21 Lu-Emerson, Snuderl, Kirkpatrick, Goveia, Davidson, Huang (bib0380) 2013; 15 Hersey, Sosman, O'Day, Richards, Bedikian, Gonzalez (bib0470) 2010; 116 Priceman, Sung, Shaposhnik, Burton, Torres-Collado, Moughon (bib0530) 2010; 115 Chen, Jacamo, Konopleva, Garzon, Croce, Andreeff (bib0245) 2013; 123 Qiang, Kopantzev, Rudikoff (bib0265) 2002; 99 Song, Smith, Doshi, Sasser, Fulp, Altiok (bib0425) 2014; 9 Pyonteck, Akkari, Schuhmacher, Bowman, Sevenich, Quail (bib0510) 2013; 19 Mulligan, Day, Gillespie, Rosenzweig, Young (bib0195) 2009; 70 Amin, Hida, Bielenberg, Klagsbrun (bib0165) 2006; 66 Mantovani, Allavena (bib0120) 2015; 212 Podar, Tai, Davies, Lentzsch, Sattler, Hideshima (bib0260) 2001; 98 Netti, Berk, Swartz, Grodzinsky, Jain (bib0220) 2000; 60 Fukunaga-Kalabis, Martinez, Nguyen, Kim, Santiago-Walker, Roesch (bib0320) 2010; 29 Kalluri, Zeisberg (bib0045) 2006; 6 Brana, Calles, LoRusso, Yee, Puchalski, Seetharam (bib0505) 2015; 10 Straussman, Morikawa, Shee, Barzily-Rokni, Qian, Du (bib0070) 2012; 487 Akiyama, Ohga, Hida, Kawamoto, Sadamoto, Ishikawa (bib0170) 2012; 180 de la Fuente, Casanova, Moyano, Garcia-Gila, Sanz, Garcia-Marco (bib0300) 2002; 71 DeNardo, Brennan, Rexhepaj, Ruffell, Shiao, Madden (bib0110) 2011; 1 Ries, Cannarile, Hoves, Benz, Wartha, Runza (bib0480) 2014; 25 Gabrusiewicz, Liu, Cortes-Santiago, Hossain, Conrad, Aldape (bib0375) 2014; 5 Pienta, Machiels, Schrijvers, Alekseev, Shkolnik, Crabb (bib0500) 2013; 31 Loeffler, Kruger, Niethammer, Reisfeld (bib0335) 2006; 116 Beatty, Chiorean, Fishman, Saboury, Teitelbaum, Sun (bib0515) 2011; 331 Nagaraj, Youn, Weber, Iclozan, Lu, Cotter (bib0565) 2010; 16 Nefedova, Fishman, Sherman, Wang, Beg, Gabrilovich (bib0570) 2007; 67 Sica, Larghi, Mancino, Rubino, Porta, Totaro (bib0090) 2008; 18 Acharyya, Oskarsson, Vanharanta, Malladi, Kim, Morris (bib0150) 2012; 150 Chung, Wu, Zhuang, Ngu, Kasman, Zhang (bib0390) 2013; 19 Kroemer, Galluzzi, Kepp, Zitvogel (bib0590) 2013; 31 Anderberg, Pietras (bib0060) 2009; 8 Zhan, Wang, Lv, Wang, Qiu, Lin (bib0035) 2009; 4 Mantovani, Biswas, Galdiero, Sica, Locati (bib0105) 2013; 229 Shojaei, Wu, Zhong, Yu, Liang, Yao (bib0385) 2007; 450 Fukumura, Xavier, Sugiura, Chen, Park, Lu (bib0030) 1998; 94 Weigelt, Lo, Park, Gray, Bissell (bib0440) 2010; 122 Paraiso, Smalley (bib0075) 2013; 85 Scalici, Harrer, Allen, Jazaeri, Atkins, McLachlan (bib0450) 2014; 132 Ruffell, Chang-Strachan, Chan, Rosenbusch, Ho, Pryer (bib0360) 2014; 26 Ogata, Chauhan, Teoh, Treon, Urashima, Schlossman (bib0255) 1997; 159 Klemm, Joyce (bib0350) 2015; 25 Iclozan, Antonia, Chiappori, Chen, Gabrilovich (bib0580) 2013; 62 Dancescu, Rubio-Trujillo, Biron, Bron, Delespesse, Sarfati (bib0270) 1992; 176 Rasanen, Vaheri (bib0055) 2010; 316 Grantab, Sivananthan, Tannock (bib0215) 2006; 66 Mulligan, Young (bib0200) 2010; 59 Serafini, Meckel, Kelso, Noonan, Califano, Koch (bib0560) 2006; 203 Meads, Gatenby, Dalton (bib0230) 2009; 9 Finke, Ko, Rini, Rayman, Ireland, Cohen (bib0155) 2011; 11 Des Guetz, Uzzan, Nicolas, Cucherat, Morere, Benamouzig (bib0040) 2006; 94 Paulus, Stanley, Schafer, Abraham, Aharinejad (bib0125) 2006; 66 Ma, Galluzzi, Zitvogel, Kroemer (bib0600) 2013; 39 Hodkinson, Elliott, Wong, Rintoul, Mackinnon, Haslett (bib0310) 2006; 13 Sandhu, Papadopoulos, Fong, Patnaik, Messiou, Olmos (bib0495) 2013; 71 Beatty, Torigian, Chiorean, Saboury, Brothers, Alavi (bib0520) 2013; 19 Highfill, Cui, Giles, Smith, Zhang, Morse (bib0540) 2014; 6 Jinushi, Chiba, Yoshiyama, Masutomi, Kinoshita, Dosaka-Akita (bib0365) 2011; 108 Aoudjit, Vuori (bib0315) 2001; 20 Qin, Lerman, Sakamaki, Wei, Cha, Rao (bib0550) 2014; 20 Erez, Glanz, Raz, Avivi, Barshack (bib0065) 2013; 437 Hanahan, Weinberg (bib0020) 2011; 144 Bisping, Wenning, Kropff, Gustavus, Muller-Tidow, Stelljes (bib0420) 2009; 15 Pallasch, Leskov, Braun, Vorholt, Drake, Soto-Feliciano (bib0610) 2014; 156 Hannesdottir, Tymoszuk, Parajuli, Wasmer, Philipp, Daschil (bib0605) 2013; 43 Burger, Hartmann, Krome, Rawluk, Tamamura, Fujii (bib0400) 2005; 106 Hsieh, Gang, Geng, Park, Huantes, Chudziak (bib0455) 2013; 121 Shojaei, Wu, Qu, Kowanetz, Yu, Tan (bib0145) 2009; 106 Park, Zhang, Yao, Park, Bissell (bib0435) 2008; 68 Duluc, Corvaisier, Blanchard, Catala, Descamps, Gamelin (bib0095) 2009; 125 Zhang, Wu, Guan, Wang, Ren, Shi (bib0295) 2015; 6 Stupp, Hegi, Gorlia, Erridge, Perry, Hong (bib0475) 2014; 15 Cassier, Italiano, Gomez-Roca, Le Tourneau, Toulmonde, Cannarile (bib0485) 2015; 16 Rodig, Ryan, Allen, Pang, Grabie, Chernova (bib0190) 2003; 33 Quail, Joyce (bib0015) 2013; 19 Uy, Rettig, Motabi, McFarland, Trinkaus, Hladnik (bib0410) 2012; 119 Ostuni, Kratochvill, Murray, Natoli (bib0085) 2015; 36 Turley, Cremasco, Astarita (bib0175) 2015; 15 Bissell, Radisky (bib0205) 2001; 1 Dijkgraaf, Heusinkveld, Tummers, Vogelpoel, Goedemans, Jha (bib0115) 2013; 73 Dankbar, Padro, Leo, Feldmann, Kropff, Mesters (bib0285) 2000; 95 Ko, Kim, Kim, Chang, Ko, Chang (bib0585) 2007; 67 Hagemann, Lawrence, McNeish, Charles, Kulbe, Thompson (bib0100) 2008; 205 Berube, Talbot, Collin, Paquet-Bouchard, Germain, Guerin (bib0325) 2005; 26 Gabrilovich, Ostrand-Rosenberg, Bronte (bib0140) 2012; 12 Berk, Yuan, Leunig, Jain (bib0225) 1997; 94 Zigrino, Nischt, Mauch (bib0345) 2011; 286 Sumida, Wakita, Narita, Masuko, Terada, Watanabe (bib0535) 2012; 42 Zeng, Shi, Samudio, Wang, Ling, Frolova (bib0405) 2009; 113 Tredan, Galmarini, Patel, Tannock (bib0025) 2007; 99 Moisan, Francisco, Brozovic, Duran, Wang, Chaturvedi (bib0490) 2014; 8 Kalluri (10.1016/j.canlet.2016.01.043_bib0045) 2006; 6 Kroemer (10.1016/j.canlet.2016.01.043_bib0590) 2013; 31 Hanahan (10.1016/j.canlet.2016.01.043_bib0020) 2011; 144 Podar (10.1016/j.canlet.2016.01.043_bib0260) 2001; 98 Serafini (10.1016/j.canlet.2016.01.043_bib0560) 2006; 203 Gabrilovich (10.1016/j.canlet.2016.01.043_bib0140) 2012; 12 Grantab (10.1016/j.canlet.2016.01.043_bib0215) 2006; 66 Dancescu (10.1016/j.canlet.2016.01.043_bib0270) 1992; 176 Moisan (10.1016/j.canlet.2016.01.043_bib0490) 2014; 8 Duluc (10.1016/j.canlet.2016.01.043_bib0095) 2009; 125 Margolin (10.1016/j.canlet.2016.01.043_bib0250) 2011; 13 Weigelt (10.1016/j.canlet.2016.01.043_bib0440) 2010; 122 Hannesdottir (10.1016/j.canlet.2016.01.043_bib0605) 2013; 43 Chung (10.1016/j.canlet.2016.01.043_bib0390) 2013; 19 Brana (10.1016/j.canlet.2016.01.043_bib0505) 2015; 10 Matsunaga (10.1016/j.canlet.2016.01.043_bib0305) 2003; 9 Hodkinson (10.1016/j.canlet.2016.01.043_bib0310) 2006; 13 Bisping (10.1016/j.canlet.2016.01.043_bib0420) 2009; 15 Highfill (10.1016/j.canlet.2016.01.043_bib0540) 2014; 6 Berk (10.1016/j.canlet.2016.01.043_bib0225) 1997; 94 Hsieh (10.1016/j.canlet.2016.01.043_bib0455) 2013; 121 Beatty (10.1016/j.canlet.2016.01.043_bib0515) 2011; 331 Nagaraj (10.1016/j.canlet.2016.01.043_bib0565) 2010; 16 Zhang (10.1016/j.canlet.2016.01.043_bib0295) 2015; 6 Hersey (10.1016/j.canlet.2016.01.043_bib0470) 2010; 116 Nefedova (10.1016/j.canlet.2016.01.043_bib0570) 2007; 67 Shojaei (10.1016/j.canlet.2016.01.043_bib0145) 2009; 106 Burger (10.1016/j.canlet.2016.01.043_bib0235) 2000; 96 Ostuni (10.1016/j.canlet.2016.01.043_bib0085) 2015; 36 Zigrino (10.1016/j.canlet.2016.01.043_bib0345) 2011; 286 Griffioen (10.1016/j.canlet.2016.01.043_bib0180) 1996; 88 Berube (10.1016/j.canlet.2016.01.043_bib0325) 2005; 26 Cassier (10.1016/j.canlet.2016.01.043_bib0485) 2015; 16 Sumida (10.1016/j.canlet.2016.01.043_bib0535) 2012; 42 Paulus (10.1016/j.canlet.2016.01.043_bib0125) 2006; 66 Rasanen (10.1016/j.canlet.2016.01.043_bib0055) 2010; 316 Park (10.1016/j.canlet.2016.01.043_bib0435) 2008; 68 Bayne (10.1016/j.canlet.2016.01.043_bib0525) 2012; 21 Song (10.1016/j.canlet.2016.01.043_bib0425) 2014; 9 Nishio (10.1016/j.canlet.2016.01.043_bib0240) 2005; 106 Weizman (10.1016/j.canlet.2016.01.043_bib0370) 2014; 33 Talmadge (10.1016/j.canlet.2016.01.043_bib0185) 2013; 13 Beatty (10.1016/j.canlet.2016.01.043_bib0520) 2013; 19 Mantovani (10.1016/j.canlet.2016.01.043_bib0120) 2015; 212 Bissell (10.1016/j.canlet.2016.01.043_bib0205) 2001; 1 Ma (10.1016/j.canlet.2016.01.043_bib0600) 2013; 39 Nakasone (10.1016/j.canlet.2016.01.043_bib0355) 2012; 21 Fukumura (10.1016/j.canlet.2016.01.043_bib0030) 1998; 94 Bracci (10.1016/j.canlet.2016.01.043_bib0595) 2014; 21 Alva (10.1016/j.canlet.2016.01.043_bib0460) 2012; 30 Turley (10.1016/j.canlet.2016.01.043_bib0175) 2015; 15 Jewell (10.1016/j.canlet.2016.01.043_bib0275) 1994; 88 Shojaei (10.1016/j.canlet.2016.01.043_bib0385) 2007; 450 Zhan (10.1016/j.canlet.2016.01.043_bib0035) 2009; 4 Lu-Emerson (10.1016/j.canlet.2016.01.043_bib0380) 2013; 15 Ko (10.1016/j.canlet.2016.01.043_bib0585) 2007; 67 Tredan (10.1016/j.canlet.2016.01.043_bib0025) 2007; 99 Burger (10.1016/j.canlet.2016.01.043_bib0400) 2005; 106 DeNardo (10.1016/j.canlet.2016.01.043_bib0110) 2011; 1 Ruffell (10.1016/j.canlet.2016.01.043_bib0360) 2014; 26 Zeng (10.1016/j.canlet.2016.01.043_bib0405) 2009; 113 Akino (10.1016/j.canlet.2016.01.043_bib0160) 2009; 175 Chen (10.1016/j.canlet.2016.01.043_bib0245) 2013; 123 Straussman (10.1016/j.canlet.2016.01.043_bib0070) 2012; 487 de la Fuente (10.1016/j.canlet.2016.01.043_bib0300) 2002; 71 Pallasch (10.1016/j.canlet.2016.01.043_bib0610) 2014; 156 Des Guetz (10.1016/j.canlet.2016.01.043_bib0040) 2006; 94 Qian (10.1016/j.canlet.2016.01.043_bib0080) 2010; 141 Podar (10.1016/j.canlet.2016.01.043_bib0445) 2011; 155 Mantovani (10.1016/j.canlet.2016.01.043_bib0105) 2013; 229 Gabrusiewicz (10.1016/j.canlet.2016.01.043_bib0375) 2014; 5 Obermajer (10.1016/j.canlet.2016.01.043_bib0545) 2011; 71 Aoudjit (10.1016/j.canlet.2016.01.043_bib0315) 2001; 20 Ogata (10.1016/j.canlet.2016.01.043_bib0255) 1997; 159 Pienta (10.1016/j.canlet.2016.01.043_bib0500) 2013; 31 Netti (10.1016/j.canlet.2016.01.043_bib0220) 2000; 60 Paraiso (10.1016/j.canlet.2016.01.043_bib0075) 2013; 85 Mulligan (10.1016/j.canlet.2016.01.043_bib0200) 2010; 59 Mulligan (10.1016/j.canlet.2016.01.043_bib0195) 2009; 70 Sica (10.1016/j.canlet.2016.01.043_bib0090) 2008; 18 Klemm (10.1016/j.canlet.2016.01.043_bib0350) 2015; 25 Akiyama (10.1016/j.canlet.2016.01.043_bib0170) 2012; 180 Bisping (10.1016/j.canlet.2016.01.043_bib0290) 2003; 101 Priceman (10.1016/j.canlet.2016.01.043_bib0530) 2010; 115 Anderberg (10.1016/j.canlet.2016.01.043_bib0060) 2009; 8 Rodig (10.1016/j.canlet.2016.01.043_bib0190) 2003; 33 Jinushi (10.1016/j.canlet.2016.01.043_bib0365) 2011; 108 Scalici (10.1016/j.canlet.2016.01.043_bib0450) 2014; 132 Iclozan (10.1016/j.canlet.2016.01.043_bib0580) 2013; 62 Hagemann (10.1016/j.canlet.2016.01.043_bib0100) 2008; 205 Hanahan (10.1016/j.canlet.2016.01.043_bib0010) 2012; 21 Lin (10.1016/j.canlet.2016.01.043_bib0415) 2002; 62 Dijkgraaf (10.1016/j.canlet.2016.01.043_bib0115) 2013; 73 Qin (10.1016/j.canlet.2016.01.043_bib0550) 2014; 20 Loeffler (10.1016/j.canlet.2016.01.043_bib0335) 2006; 116 Sandhu (10.1016/j.canlet.2016.01.043_bib0495) 2013; 71 Pyonteck (10.1016/j.canlet.2016.01.043_bib0510) 2013; 19 Amin (10.1016/j.canlet.2016.01.043_bib0165) 2006; 66 Uy (10.1016/j.canlet.2016.01.043_bib0410) 2012; 119 Hudes (10.1016/j.canlet.2016.01.043_bib0430) 2013; 31 Finke (10.1016/j.canlet.2016.01.043_bib0155) 2011; 11 Stupp (10.1016/j.canlet.2016.01.043_bib0475) 2014; 15 Shree (10.1016/j.canlet.2016.01.043_bib0135) 2011; 25 Bruchard (10.1016/j.canlet.2016.01.043_bib0395) 2013; 19 Fukunaga-Kalabis (10.1016/j.canlet.2016.01.043_bib0320) 2010; 29 Orimo (10.1016/j.canlet.2016.01.043_bib0050) 2005; 121 Konig (10.1016/j.canlet.2016.01.043_bib0280) 1997; 11 Shojaei (10.1016/j.canlet.2016.01.043_bib0130) 2007; 25 Dankbar (10.1016/j.canlet.2016.01.043_bib0285) 2000; 95 Meads (10.1016/j.canlet.2016.01.043_bib0230) 2009; 9 Sherman-Baust (10.1016/j.canlet.2016.01.043_bib0330) 2003; 3 Eisele (10.1016/j.canlet.2016.01.043_bib0465) 2014; 117 Fujita (10.1016/j.canlet.2016.01.043_bib0555) 2011; 71 Ries (10.1016/j.canlet.2016.01.043_bib0480) 2014; 25 Misra (10.1016/j.canlet.2016.01.043_bib0340) 2003; 278 Acharyya (10.1016/j.canlet.2016.01.043_bib0150) 2012; 150 Quail (10.1016/j.canlet.2016.01.043_bib0015) 2013; 19 Erez (10.1016/j.canlet.2016.01.043_bib0065) 2013; 437 Qiang (10.1016/j.canlet.2016.01.043_bib0265) 2002; 99 Kim (10.1016/j.canlet.2016.01.043_bib0210) 2011; 209 Lathers (10.1016/j.canlet.2016.01.043_bib0575) 2004; 53 |
| References_xml | – volume: 209 start-page: 139 year: 2011 end-page: 151 ident: bib0210 article-title: Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor publication-title: J. Endocrinol – volume: 155 start-page: 438 year: 2011 end-page: 448 ident: bib0445 article-title: The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications publication-title: Br. J. Haematol – volume: 156 start-page: 590 year: 2014 end-page: 602 ident: bib0610 article-title: Sensitizing protective tumor microenvironments to antibody-mediated therapy publication-title: Cell – volume: 85 start-page: 1033 year: 2013 end-page: 1041 ident: bib0075 article-title: Fibroblast-mediated drug resistance in cancer publication-title: Biochem. Pharmacol – volume: 286 start-page: 6801 year: 2011 end-page: 6807 ident: bib0345 article-title: The disintegrin-like and cysteine-rich domains of ADAM-9 mediate interactions between melanoma cells and fibroblasts publication-title: J. Biol. Chem – volume: 19 start-page: 1114 year: 2013 end-page: 1123 ident: bib0390 article-title: An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy publication-title: Nat. Med – volume: 60 start-page: 2497 year: 2000 end-page: 2503 ident: bib0220 article-title: Role of extracellular matrix assembly in interstitial transport in solid tumors publication-title: Cancer Res – volume: 106 start-page: 1824 year: 2005 end-page: 1830 ident: bib0400 article-title: Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells publication-title: Blood – volume: 18 start-page: 349 year: 2008 end-page: 355 ident: bib0090 article-title: Macrophage polarization in tumour progression publication-title: Semin. Cancer Biol – volume: 5 start-page: 2208 year: 2014 end-page: 2220 ident: bib0375 article-title: Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes publication-title: Oncotarget – volume: 229 start-page: 176 year: 2013 end-page: 185 ident: bib0105 article-title: Macrophage plasticity and polarization in tissue repair and remodelling publication-title: J. Pathol – volume: 123 start-page: 2395 year: 2013 end-page: 2407 ident: bib0245 article-title: CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia publication-title: J. Clin. Invest – volume: 71 start-page: 1041 year: 2013 end-page: 1050 ident: bib0495 article-title: A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors publication-title: Cancer Chemother. Pharmacol – volume: 26 start-page: 623 year: 2014 end-page: 637 ident: bib0360 article-title: Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells publication-title: Cancer Cell – volume: 4 start-page: 1094 year: 2009 end-page: 1103 ident: bib0035 article-title: Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis publication-title: J. Thorac. Oncol – volume: 6 start-page: 392 year: 2006 end-page: 401 ident: bib0045 article-title: Fibroblasts in cancer publication-title: Nat. Rev. Cancer – volume: 150 start-page: 165 year: 2012 end-page: 178 ident: bib0150 article-title: A CXCL1 paracrine network links cancer chemoresistance and metastasis publication-title: Cell – volume: 62 start-page: 909 year: 2013 end-page: 918 ident: bib0580 article-title: Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer publication-title: Cancer Immunol. Immunother – volume: 62 start-page: 5019 year: 2002 end-page: 5026 ident: bib0415 article-title: The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment publication-title: Cancer Res – volume: 159 start-page: 2212 year: 1997 end-page: 2221 ident: bib0255 article-title: IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade publication-title: J. Immunol – volume: 67 start-page: 7477 year: 2007 end-page: 7486 ident: bib0585 article-title: A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model publication-title: Cancer Res – volume: 96 start-page: 2655 year: 2000 end-page: 2663 ident: bib0235 article-title: Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1 publication-title: Blood – volume: 94 start-page: 1785 year: 1997 end-page: 1790 ident: bib0225 article-title: Direct publication-title: Proc. Natl. Acad. Sci. U.S.A. – volume: 101 start-page: 2775 year: 2003 end-page: 2783 ident: bib0290 article-title: Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma publication-title: Blood – volume: 66 start-page: 1033 year: 2006 end-page: 1039 ident: bib0215 article-title: The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells publication-title: Cancer Res – volume: 212 start-page: 435 year: 2015 end-page: 445 ident: bib0120 article-title: The interaction of anticancer therapies with tumor-associated macrophages publication-title: J. Exp. Med – volume: 3 start-page: 377 year: 2003 end-page: 386 ident: bib0330 article-title: Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells publication-title: Cancer Cell – volume: 39 start-page: 211 year: 2013 end-page: 227 ident: bib0600 article-title: Autophagy and cellular immune responses publication-title: Immunity – volume: 20 start-page: 4995 year: 2001 end-page: 5004 ident: bib0315 article-title: Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells publication-title: Oncogene – volume: 108 start-page: 12425 year: 2011 end-page: 12430 ident: bib0365 article-title: Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells publication-title: Proc. Natl. Acad. Sci. U.S.A. – volume: 125 start-page: 367 year: 2009 end-page: 373 ident: bib0095 article-title: Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages publication-title: Int. J. Cancer – volume: 132 start-page: 455 year: 2014 end-page: 461 ident: bib0450 article-title: Inhibition of alpha4beta1 integrin increases ovarian cancer response to carboplatin publication-title: Gynecol. Oncol – volume: 316 start-page: 2713 year: 2010 end-page: 2722 ident: bib0055 article-title: Activation of fibroblasts in cancer stroma publication-title: Exp. Cell Res – volume: 70 start-page: 375 year: 2009 end-page: 382 ident: bib0195 article-title: Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions publication-title: Hum. Immunol – volume: 9 start-page: 665 year: 2009 end-page: 674 ident: bib0230 article-title: Environment-mediated drug resistance: a major contributor to minimal residual disease publication-title: Nat. Rev. Cancer – volume: 95 start-page: 2630 year: 2000 end-page: 2636 ident: bib0285 article-title: Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma publication-title: Blood – volume: 21 start-page: 15 year: 2014 end-page: 25 ident: bib0595 article-title: Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer publication-title: Cell Death Differ – volume: 15 start-page: 1100 year: 2014 end-page: 1108 ident: bib0475 article-title: Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial publication-title: Lancet Oncol – volume: 25 start-page: 198 year: 2015 end-page: 213 ident: bib0350 article-title: Microenvironmental regulation of therapeutic response in cancer publication-title: Trends Cell Biol – volume: 43 start-page: 2718 year: 2013 end-page: 2729 ident: bib0605 article-title: Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response publication-title: Eur. J. Immunol – volume: 98 start-page: 428 year: 2001 end-page: 435 ident: bib0260 article-title: Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration publication-title: Blood – volume: 13 start-page: 1776 year: 2006 end-page: 1788 ident: bib0310 article-title: ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase publication-title: Cell Death Differ – volume: 117 start-page: 141 year: 2014 end-page: 145 ident: bib0465 article-title: Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression publication-title: J. Neurooncol – volume: 99 start-page: 1441 year: 2007 end-page: 1454 ident: bib0025 article-title: Drug resistance and the solid tumor microenvironment publication-title: J. Natl. Cancer Inst – volume: 73 start-page: 2480 year: 2013 end-page: 2492 ident: bib0115 article-title: Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment publication-title: Cancer Res – volume: 15 start-page: 1079 year: 2013 end-page: 1087 ident: bib0380 article-title: Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma publication-title: Neuro Oncol – volume: 8 start-page: 1231 year: 2014 end-page: 1239 ident: bib0490 article-title: Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers publication-title: Mol. Oncol – volume: 9 start-page: 974 year: 2014 end-page: 982 ident: bib0425 article-title: Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer publication-title: J. Thorac. Oncol – volume: 31 start-page: 760 year: 2013 end-page: 768 ident: bib0500 article-title: Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer publication-title: Invest. New Drugs – volume: 11 start-page: 856 year: 2011 end-page: 861 ident: bib0155 article-title: MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy publication-title: Int. Immunopharmacol – volume: 59 start-page: 267 year: 2010 end-page: 277 ident: bib0200 article-title: Tumors induce the formation of suppressor endothelial cells publication-title: Cancer Immunol. Immunother – volume: 487 start-page: 500 year: 2012 end-page: 504 ident: bib0070 article-title: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion publication-title: Nature – volume: 99 start-page: 4138 year: 2002 end-page: 4146 ident: bib0265 article-title: Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk publication-title: Blood – volume: 122 start-page: 35 year: 2010 end-page: 43 ident: bib0440 article-title: HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment publication-title: Breast Cancer Res. Treat – volume: 19 start-page: 57 year: 2013 end-page: 64 ident: bib0395 article-title: Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth publication-title: Nat. Med – volume: 6 start-page: 3085 year: 2015 end-page: 3097 ident: bib0295 article-title: Paracrine SDF-1alpha signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells publication-title: Oncotarget – volume: 71 start-page: 495 year: 2002 end-page: 502 ident: bib0300 article-title: Engagement of alpha4beta1 integrin by fibronectin induces publication-title: J. Leukoc. Biol – volume: 106 start-page: 6742 year: 2009 end-page: 6747 ident: bib0145 article-title: G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models publication-title: Proc. Natl. Acad. Sci. U.S.A. – volume: 116 start-page: 1526 year: 2010 end-page: 1534 ident: bib0470 article-title: A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or − dacarbazine in patients with stage IV metastatic melanoma publication-title: Cancer – volume: 115 start-page: 1461 year: 2010 end-page: 1471 ident: bib0530 article-title: Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy publication-title: Blood – volume: 42 start-page: 2060 year: 2012 end-page: 2072 ident: bib0535 article-title: Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses publication-title: Eur. J. Immunol – volume: 25 start-page: 846 year: 2014 end-page: 859 ident: bib0480 article-title: Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy publication-title: Cancer Cell – volume: 88 start-page: 268 year: 1994 end-page: 274 ident: bib0275 article-title: Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis publication-title: Br. J. Haematol – volume: 9 start-page: 1158 year: 2003 end-page: 1165 ident: bib0305 article-title: Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia publication-title: Nat. Med – volume: 66 start-page: 4349 year: 2006 end-page: 4356 ident: bib0125 article-title: Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts publication-title: Cancer Res – volume: 11 start-page: 258 year: 1997 end-page: 265 ident: bib0280 article-title: Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis publication-title: Leukemia – volume: 119 start-page: 3917 year: 2012 end-page: 3924 ident: bib0410 article-title: A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia publication-title: Blood – volume: 33 start-page: 3117 year: 2003 end-page: 3126 ident: bib0190 article-title: Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis publication-title: Eur. J. Immunol – volume: 21 start-page: 309 year: 2012 end-page: 322 ident: bib0010 article-title: Accessories to the crime: functions of cells recruited to the tumor microenvironment publication-title: Cancer Cell – volume: 13 start-page: 739 year: 2013 end-page: 752 ident: bib0185 article-title: History of myeloid-derived suppressor cells publication-title: Nat. Rev. Cancer – volume: 19 start-page: 1423 year: 2013 end-page: 1437 ident: bib0015 article-title: Microenvironmental regulation of tumor progression and metastasis publication-title: Nat. Med – volume: 71 start-page: 7463 year: 2011 end-page: 7470 ident: bib0545 article-title: PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment publication-title: Cancer Res – volume: 67 start-page: 11021 year: 2007 end-page: 11028 ident: bib0570 article-title: Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells publication-title: Cancer Res – volume: 94 start-page: 715 year: 1998 end-page: 725 ident: bib0030 article-title: Tumor induction of VEGF promoter activity in stromal cells publication-title: Cell – volume: 15 start-page: 520 year: 2009 end-page: 531 ident: bib0420 article-title: Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma publication-title: Clin. Cancer Res – volume: 15 start-page: 669 year: 2015 end-page: 682 ident: bib0175 article-title: Immunological hallmarks of stromal cells in the tumour microenvironment publication-title: Nat. Rev. Immunol – volume: 121 start-page: 1814 year: 2013 end-page: 1818 ident: bib0455 article-title: Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy publication-title: Blood – volume: 16 start-page: 949 year: 2015 end-page: 956 ident: bib0485 article-title: CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study publication-title: Lancet Oncol – volume: 68 start-page: 4398 year: 2008 end-page: 4405 ident: bib0435 article-title: Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts publication-title: Cancer Res – volume: 19 start-page: 1264 year: 2013 end-page: 1272 ident: bib0510 article-title: CSF-1R inhibition alters macrophage polarization and blocks glioma progression publication-title: Nat. Med – volume: 71 start-page: 2664 year: 2011 end-page: 2674 ident: bib0555 article-title: COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells publication-title: Cancer Res – volume: 25 start-page: 911 year: 2007 end-page: 920 ident: bib0130 article-title: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells publication-title: Nat. Biotechnol – volume: 12 start-page: 253 year: 2012 end-page: 268 ident: bib0140 article-title: Coordinated regulation of myeloid cells by tumours publication-title: Nat. Rev. Immunol – volume: 21 start-page: 822 year: 2012 end-page: 835 ident: bib0525 article-title: Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer publication-title: Cancer Cell – volume: 175 start-page: 2657 year: 2009 end-page: 2667 ident: bib0160 article-title: Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors publication-title: Am. J. Pathol – volume: 94 start-page: 1823 year: 2006 end-page: 1832 ident: bib0040 article-title: Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature publication-title: Br. J. Cancer – volume: 10 start-page: 111 year: 2015 end-page: 123 ident: bib0505 article-title: Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study publication-title: Target. Oncol – volume: 21 start-page: 488 year: 2012 end-page: 503 ident: bib0355 article-title: Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance publication-title: Cancer Cell – volume: 176 start-page: 1319 year: 1992 end-page: 1326 ident: bib0270 article-title: Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression publication-title: J. Exp. Med – volume: 16 start-page: 1812 year: 2010 end-page: 1823 ident: bib0565 article-title: Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer publication-title: Clin. Cancer Res – volume: 106 start-page: 1012 year: 2005 end-page: 1020 ident: bib0240 article-title: Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha publication-title: Blood – volume: 6 start-page: 237ra267 year: 2014 ident: bib0540 article-title: Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy publication-title: Sci. Transl. Med – volume: 31 start-page: 669 year: 2013 end-page: 676 ident: bib0430 article-title: A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer publication-title: Invest. New Drugs – volume: 33 start-page: 3812 year: 2014 end-page: 3819 ident: bib0370 article-title: Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase publication-title: Oncogene – volume: 180 start-page: 1283 year: 2012 end-page: 1293 ident: bib0170 article-title: Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment publication-title: Am. J. Pathol – volume: 30 start-page: 749 year: 2012 end-page: 757 ident: bib0460 article-title: Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium publication-title: Invest. New Drugs – volume: 88 start-page: 667 year: 1996 end-page: 673 ident: bib0180 article-title: Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium publication-title: Blood – volume: 31 start-page: 51 year: 2013 end-page: 72 ident: bib0590 article-title: Immunogenic cell death in cancer therapy publication-title: Annu. Rev. Immunol – volume: 116 start-page: 1955 year: 2006 end-page: 1962 ident: bib0335 article-title: Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake publication-title: J. Clin. Invest – volume: 144 start-page: 646 year: 2011 end-page: 674 ident: bib0020 article-title: Hallmarks of cancer: the next generation publication-title: Cell – volume: 1 start-page: 54 year: 2011 end-page: 67 ident: bib0110 article-title: Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy publication-title: Cancer Discov – volume: 53 start-page: 422 year: 2004 end-page: 430 ident: bib0575 article-title: Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3 publication-title: Cancer Immunol. Immunother – volume: 8 start-page: 1461 year: 2009 end-page: 1462 ident: bib0060 article-title: On the origin of cancer-associated fibroblasts publication-title: Cell Cycle – volume: 331 start-page: 1612 year: 2011 end-page: 1616 ident: bib0515 article-title: CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans publication-title: Science – volume: 205 start-page: 1261 year: 2008 end-page: 1268 ident: bib0100 article-title: “Re-educating” tumor-associated macrophages by targeting NF-kappaB publication-title: J. Exp. Med – volume: 25 start-page: 2465 year: 2011 end-page: 2479 ident: bib0135 article-title: Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer publication-title: Genes Dev – volume: 437 start-page: 397 year: 2013 end-page: 402 ident: bib0065 article-title: Cancer associated fibroblasts express pro-inflammatory factors in human breast and ovarian tumors publication-title: Biochem. Biophys. Res. Commun – volume: 121 start-page: 335 year: 2005 end-page: 348 ident: bib0050 article-title: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion publication-title: Cell – volume: 113 start-page: 6215 year: 2009 end-page: 6224 ident: bib0405 article-title: Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML publication-title: Blood – volume: 1 start-page: 46 year: 2001 end-page: 54 ident: bib0205 article-title: Putting tumours in context publication-title: Nat. Rev. Cancer – volume: 13 start-page: 874 year: 2011 end-page: 886 ident: bib0250 article-title: Lymph node stromal cells enhance drug-resistant colon cancer cell tumor formation through SDF-1alpha/CXCR4 paracrine signaling publication-title: Neoplasia – volume: 20 start-page: 676 year: 2014 end-page: 681 ident: bib0550 article-title: Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice publication-title: Nat. Med – volume: 66 start-page: 2173 year: 2006 end-page: 2180 ident: bib0165 article-title: Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors publication-title: Cancer Res – volume: 141 start-page: 39 year: 2010 end-page: 51 ident: bib0080 article-title: Macrophage diversity enhances tumor progression and metastasis publication-title: Cell – volume: 36 start-page: 229 year: 2015 end-page: 239 ident: bib0085 article-title: Macrophages and cancer: from mechanisms to therapeutic implications publication-title: Trends Immunol – volume: 19 start-page: 6286 year: 2013 end-page: 6295 ident: bib0520 article-title: A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma publication-title: Clin. Cancer Res – volume: 450 start-page: 825 year: 2007 end-page: 831 ident: bib0385 article-title: Bv8 regulates myeloid-cell-dependent tumour angiogenesis publication-title: Nature – volume: 278 start-page: 25285 year: 2003 end-page: 25288 ident: bib0340 article-title: Regulation of multidrug resistance in cancer cells by hyaluronan publication-title: J. Biol. Chem – volume: 203 start-page: 2691 year: 2006 end-page: 2702 ident: bib0560 article-title: Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function publication-title: J. Exp. Med – volume: 26 start-page: 405 year: 2005 end-page: 413 ident: bib0325 article-title: Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin publication-title: Int. J. Oncol – volume: 29 start-page: 6115 year: 2010 end-page: 6124 ident: bib0320 article-title: Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population publication-title: Oncogene – volume: 175 start-page: 2657 year: 2009 ident: 10.1016/j.canlet.2016.01.043_bib0160 article-title: Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors publication-title: Am. J. Pathol doi: 10.2353/ajpath.2009.090202 – volume: 19 start-page: 57 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0395 article-title: Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth publication-title: Nat. Med doi: 10.1038/nm.2999 – volume: 16 start-page: 949 year: 2015 ident: 10.1016/j.canlet.2016.01.043_bib0485 article-title: CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00132-1 – volume: 1 start-page: 46 year: 2001 ident: 10.1016/j.canlet.2016.01.043_bib0205 article-title: Putting tumours in context publication-title: Nat. Rev. Cancer doi: 10.1038/35094059 – volume: 11 start-page: 856 year: 2011 ident: 10.1016/j.canlet.2016.01.043_bib0155 article-title: MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy publication-title: Int. Immunopharmacol doi: 10.1016/j.intimp.2011.01.030 – volume: 119 start-page: 3917 year: 2012 ident: 10.1016/j.canlet.2016.01.043_bib0410 article-title: A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia publication-title: Blood doi: 10.1182/blood-2011-10-383406 – volume: 115 start-page: 1461 year: 2010 ident: 10.1016/j.canlet.2016.01.043_bib0530 article-title: Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy publication-title: Blood doi: 10.1182/blood-2009-08-237412 – volume: 66 start-page: 2173 year: 2006 ident: 10.1016/j.canlet.2016.01.043_bib0165 article-title: Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-3387 – volume: 71 start-page: 495 year: 2002 ident: 10.1016/j.canlet.2016.01.043_bib0300 article-title: Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine publication-title: J. Leukoc. Biol doi: 10.1189/jlb.71.3.495 – volume: 141 start-page: 39 year: 2010 ident: 10.1016/j.canlet.2016.01.043_bib0080 article-title: Macrophage diversity enhances tumor progression and metastasis publication-title: Cell doi: 10.1016/j.cell.2010.03.014 – volume: 94 start-page: 715 year: 1998 ident: 10.1016/j.canlet.2016.01.043_bib0030 article-title: Tumor induction of VEGF promoter activity in stromal cells publication-title: Cell doi: 10.1016/S0092-8674(00)81731-6 – volume: 121 start-page: 335 year: 2005 ident: 10.1016/j.canlet.2016.01.043_bib0050 article-title: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion publication-title: Cell doi: 10.1016/j.cell.2005.02.034 – volume: 113 start-page: 6215 year: 2009 ident: 10.1016/j.canlet.2016.01.043_bib0405 article-title: Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML publication-title: Blood doi: 10.1182/blood-2008-05-158311 – volume: 15 start-page: 669 year: 2015 ident: 10.1016/j.canlet.2016.01.043_bib0175 article-title: Immunological hallmarks of stromal cells in the tumour microenvironment publication-title: Nat. Rev. Immunol doi: 10.1038/nri3902 – volume: 9 start-page: 1158 year: 2003 ident: 10.1016/j.canlet.2016.01.043_bib0305 article-title: Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia publication-title: Nat. Med doi: 10.1038/nm909 – volume: 62 start-page: 5019 year: 2002 ident: 10.1016/j.canlet.2016.01.043_bib0415 article-title: The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment publication-title: Cancer Res – volume: 6 start-page: 392 year: 2006 ident: 10.1016/j.canlet.2016.01.043_bib0045 article-title: Fibroblasts in cancer publication-title: Nat. Rev. Cancer doi: 10.1038/nrc1877 – volume: 31 start-page: 760 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0500 article-title: Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer publication-title: Invest. New Drugs doi: 10.1007/s10637-012-9869-8 – volume: 95 start-page: 2630 year: 2000 ident: 10.1016/j.canlet.2016.01.043_bib0285 article-title: Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma publication-title: Blood doi: 10.1182/blood.V95.8.2630 – volume: 31 start-page: 51 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0590 article-title: Immunogenic cell death in cancer therapy publication-title: Annu. Rev. Immunol doi: 10.1146/annurev-immunol-032712-100008 – volume: 25 start-page: 2465 year: 2011 ident: 10.1016/j.canlet.2016.01.043_bib0135 article-title: Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer publication-title: Genes Dev doi: 10.1101/gad.180331.111 – volume: 59 start-page: 267 year: 2010 ident: 10.1016/j.canlet.2016.01.043_bib0200 article-title: Tumors induce the formation of suppressor endothelial cells in vivo publication-title: Cancer Immunol. Immunother doi: 10.1007/s00262-009-0747-y – volume: 66 start-page: 4349 year: 2006 ident: 10.1016/j.canlet.2016.01.043_bib0125 article-title: Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-3523 – volume: 180 start-page: 1283 year: 2012 ident: 10.1016/j.canlet.2016.01.043_bib0170 article-title: Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment publication-title: Am. J. Pathol doi: 10.1016/j.ajpath.2011.11.029 – volume: 21 start-page: 15 year: 2014 ident: 10.1016/j.canlet.2016.01.043_bib0595 article-title: Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer publication-title: Cell Death Differ doi: 10.1038/cdd.2013.67 – volume: 18 start-page: 349 year: 2008 ident: 10.1016/j.canlet.2016.01.043_bib0090 article-title: Macrophage polarization in tumour progression publication-title: Semin. Cancer Biol doi: 10.1016/j.semcancer.2008.03.004 – volume: 33 start-page: 3812 year: 2014 ident: 10.1016/j.canlet.2016.01.043_bib0370 article-title: Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase publication-title: Oncogene doi: 10.1038/onc.2013.357 – volume: 21 start-page: 488 year: 2012 ident: 10.1016/j.canlet.2016.01.043_bib0355 article-title: Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance publication-title: Cancer Cell doi: 10.1016/j.ccr.2012.02.017 – volume: 6 start-page: 237ra267 year: 2014 ident: 10.1016/j.canlet.2016.01.043_bib0540 article-title: Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy publication-title: Sci. Transl. Med doi: 10.1126/scitranslmed.3007974 – volume: 88 start-page: 667 year: 1996 ident: 10.1016/j.canlet.2016.01.043_bib0180 article-title: Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium publication-title: Blood doi: 10.1182/blood.V88.2.667.bloodjournal882667 – volume: 25 start-page: 846 year: 2014 ident: 10.1016/j.canlet.2016.01.043_bib0480 article-title: Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy publication-title: Cancer Cell doi: 10.1016/j.ccr.2014.05.016 – volume: 26 start-page: 623 year: 2014 ident: 10.1016/j.canlet.2016.01.043_bib0360 article-title: Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells publication-title: Cancer Cell doi: 10.1016/j.ccell.2014.09.006 – volume: 125 start-page: 367 year: 2009 ident: 10.1016/j.canlet.2016.01.043_bib0095 article-title: Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages publication-title: Int. J. Cancer doi: 10.1002/ijc.24401 – volume: 155 start-page: 438 year: 2011 ident: 10.1016/j.canlet.2016.01.043_bib0445 article-title: The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications publication-title: Br. J. Haematol doi: 10.1111/j.1365-2141.2011.08864.x – volume: 6 start-page: 3085 year: 2015 ident: 10.1016/j.canlet.2016.01.043_bib0295 article-title: Paracrine SDF-1alpha signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells publication-title: Oncotarget doi: 10.18632/oncotarget.3099 – volume: 71 start-page: 7463 year: 2011 ident: 10.1016/j.canlet.2016.01.043_bib0545 article-title: PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-11-2449 – volume: 122 start-page: 35 year: 2010 ident: 10.1016/j.canlet.2016.01.043_bib0440 article-title: HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment publication-title: Breast Cancer Res. Treat doi: 10.1007/s10549-009-0502-2 – volume: 94 start-page: 1823 year: 2006 ident: 10.1016/j.canlet.2016.01.043_bib0040 article-title: Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature publication-title: Br. J. Cancer doi: 10.1038/sj.bjc.6603176 – volume: 53 start-page: 422 year: 2004 ident: 10.1016/j.canlet.2016.01.043_bib0575 article-title: Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3 publication-title: Cancer Immunol. Immunother doi: 10.1007/s00262-003-0459-7 – volume: 13 start-page: 739 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0185 article-title: History of myeloid-derived suppressor cells publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3581 – volume: 19 start-page: 1423 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0015 article-title: Microenvironmental regulation of tumor progression and metastasis publication-title: Nat. Med doi: 10.1038/nm.3394 – volume: 205 start-page: 1261 year: 2008 ident: 10.1016/j.canlet.2016.01.043_bib0100 article-title: “Re-educating” tumor-associated macrophages by targeting NF-kappaB publication-title: J. Exp. Med doi: 10.1084/jem.20080108 – volume: 116 start-page: 1955 year: 2006 ident: 10.1016/j.canlet.2016.01.043_bib0335 article-title: Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake publication-title: J. Clin. Invest doi: 10.1172/JCI26532 – volume: 106 start-page: 1824 year: 2005 ident: 10.1016/j.canlet.2016.01.043_bib0400 article-title: Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells publication-title: Blood doi: 10.1182/blood-2004-12-4918 – volume: 4 start-page: 1094 year: 2009 ident: 10.1016/j.canlet.2016.01.043_bib0035 article-title: Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis publication-title: J. Thorac. Oncol doi: 10.1097/JTO.0b013e3181a97e31 – volume: 123 start-page: 2395 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0245 article-title: CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia publication-title: J. Clin. Invest doi: 10.1172/JCI66553 – volume: 159 start-page: 2212 year: 1997 ident: 10.1016/j.canlet.2016.01.043_bib0255 article-title: IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade publication-title: J. Immunol doi: 10.4049/jimmunol.159.5.2212 – volume: 66 start-page: 1033 year: 2006 ident: 10.1016/j.canlet.2016.01.043_bib0215 article-title: The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-3077 – volume: 117 start-page: 141 year: 2014 ident: 10.1016/j.canlet.2016.01.043_bib0465 article-title: Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression publication-title: J. Neurooncol doi: 10.1007/s11060-014-1365-x – volume: 43 start-page: 2718 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0605 article-title: Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response publication-title: Eur. J. Immunol doi: 10.1002/eji.201242505 – volume: 71 start-page: 1041 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0495 article-title: A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors publication-title: Cancer Chemother. Pharmacol doi: 10.1007/s00280-013-2099-8 – volume: 70 start-page: 375 year: 2009 ident: 10.1016/j.canlet.2016.01.043_bib0195 article-title: Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions publication-title: Hum. Immunol doi: 10.1016/j.humimm.2009.01.014 – volume: 121 start-page: 1814 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0455 article-title: Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy publication-title: Blood doi: 10.1182/blood-2012-01-406272 – volume: 437 start-page: 397 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0065 article-title: Cancer associated fibroblasts express pro-inflammatory factors in human breast and ovarian tumors publication-title: Biochem. Biophys. Res. Commun doi: 10.1016/j.bbrc.2013.06.089 – volume: 39 start-page: 211 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0600 article-title: Autophagy and cellular immune responses publication-title: Immunity doi: 10.1016/j.immuni.2013.07.017 – volume: 31 start-page: 669 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0430 article-title: A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer publication-title: Invest. New Drugs doi: 10.1007/s10637-012-9857-z – volume: 108 start-page: 12425 year: 2011 ident: 10.1016/j.canlet.2016.01.043_bib0365 article-title: Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.1106645108 – volume: 60 start-page: 2497 year: 2000 ident: 10.1016/j.canlet.2016.01.043_bib0220 article-title: Role of extracellular matrix assembly in interstitial transport in solid tumors publication-title: Cancer Res – volume: 450 start-page: 825 year: 2007 ident: 10.1016/j.canlet.2016.01.043_bib0385 article-title: Bv8 regulates myeloid-cell-dependent tumour angiogenesis publication-title: Nature doi: 10.1038/nature06348 – volume: 286 start-page: 6801 year: 2011 ident: 10.1016/j.canlet.2016.01.043_bib0345 article-title: The disintegrin-like and cysteine-rich domains of ADAM-9 mediate interactions between melanoma cells and fibroblasts publication-title: J. Biol. Chem doi: 10.1074/jbc.M110.168617 – volume: 229 start-page: 176 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0105 article-title: Macrophage plasticity and polarization in tissue repair and remodelling publication-title: J. Pathol doi: 10.1002/path.4133 – volume: 25 start-page: 198 year: 2015 ident: 10.1016/j.canlet.2016.01.043_bib0350 article-title: Microenvironmental regulation of therapeutic response in cancer publication-title: Trends Cell Biol doi: 10.1016/j.tcb.2014.11.006 – volume: 19 start-page: 6286 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0520 article-title: A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma publication-title: Clin. Cancer Res doi: 10.1158/1078-0432.CCR-13-1320 – volume: 26 start-page: 405 year: 2005 ident: 10.1016/j.canlet.2016.01.043_bib0325 article-title: Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin publication-title: Int. J. Oncol – volume: 106 start-page: 6742 year: 2009 ident: 10.1016/j.canlet.2016.01.043_bib0145 article-title: G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.0902280106 – volume: 33 start-page: 3117 year: 2003 ident: 10.1016/j.canlet.2016.01.043_bib0190 article-title: Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis publication-title: Eur. J. Immunol doi: 10.1002/eji.200324270 – volume: 144 start-page: 646 year: 2011 ident: 10.1016/j.canlet.2016.01.043_bib0020 article-title: Hallmarks of cancer: the next generation publication-title: Cell doi: 10.1016/j.cell.2011.02.013 – volume: 99 start-page: 1441 year: 2007 ident: 10.1016/j.canlet.2016.01.043_bib0025 article-title: Drug resistance and the solid tumor microenvironment publication-title: J. Natl. Cancer Inst doi: 10.1093/jnci/djm135 – volume: 13 start-page: 874 year: 2011 ident: 10.1016/j.canlet.2016.01.043_bib0250 article-title: Lymph node stromal cells enhance drug-resistant colon cancer cell tumor formation through SDF-1alpha/CXCR4 paracrine signaling publication-title: Neoplasia doi: 10.1593/neo.11324 – volume: 132 start-page: 455 year: 2014 ident: 10.1016/j.canlet.2016.01.043_bib0450 article-title: Inhibition of alpha4beta1 integrin increases ovarian cancer response to carboplatin publication-title: Gynecol. Oncol doi: 10.1016/j.ygyno.2013.12.031 – volume: 8 start-page: 1231 year: 2014 ident: 10.1016/j.canlet.2016.01.043_bib0490 article-title: Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers publication-title: Mol. Oncol doi: 10.1016/j.molonc.2014.03.016 – volume: 209 start-page: 139 year: 2011 ident: 10.1016/j.canlet.2016.01.043_bib0210 article-title: Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor publication-title: J. Endocrinol doi: 10.1530/JOE-10-0377 – volume: 42 start-page: 2060 year: 2012 ident: 10.1016/j.canlet.2016.01.043_bib0535 article-title: Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses publication-title: Eur. J. Immunol doi: 10.1002/eji.201142335 – volume: 150 start-page: 165 year: 2012 ident: 10.1016/j.canlet.2016.01.043_bib0150 article-title: A CXCL1 paracrine network links cancer chemoresistance and metastasis publication-title: Cell doi: 10.1016/j.cell.2012.04.042 – volume: 68 start-page: 4398 year: 2008 ident: 10.1016/j.canlet.2016.01.043_bib0435 article-title: Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-6390 – volume: 30 start-page: 749 year: 2012 ident: 10.1016/j.canlet.2016.01.043_bib0460 article-title: Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium publication-title: Invest. New Drugs doi: 10.1007/s10637-010-9573-5 – volume: 101 start-page: 2775 year: 2003 ident: 10.1016/j.canlet.2016.01.043_bib0290 article-title: Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma publication-title: Blood doi: 10.1182/blood-2002-09-2907 – volume: 20 start-page: 676 year: 2014 ident: 10.1016/j.canlet.2016.01.043_bib0550 article-title: Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice publication-title: Nat. Med doi: 10.1038/nm.3560 – volume: 10 start-page: 111 year: 2015 ident: 10.1016/j.canlet.2016.01.043_bib0505 article-title: Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study publication-title: Target. Oncol doi: 10.1007/s11523-014-0320-2 – volume: 36 start-page: 229 year: 2015 ident: 10.1016/j.canlet.2016.01.043_bib0085 article-title: Macrophages and cancer: from mechanisms to therapeutic implications publication-title: Trends Immunol doi: 10.1016/j.it.2015.02.004 – volume: 106 start-page: 1012 year: 2005 ident: 10.1016/j.canlet.2016.01.043_bib0240 article-title: Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha publication-title: Blood doi: 10.1182/blood-2004-03-0889 – volume: 487 start-page: 500 year: 2012 ident: 10.1016/j.canlet.2016.01.043_bib0070 article-title: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion publication-title: Nature doi: 10.1038/nature11183 – volume: 15 start-page: 1100 year: 2014 ident: 10.1016/j.canlet.2016.01.043_bib0475 article-title: Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70379-1 – volume: 8 start-page: 1461 year: 2009 ident: 10.1016/j.canlet.2016.01.043_bib0060 article-title: On the origin of cancer-associated fibroblasts publication-title: Cell Cycle doi: 10.4161/cc.8.10.8557 – volume: 13 start-page: 1776 year: 2006 ident: 10.1016/j.canlet.2016.01.043_bib0310 article-title: ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4401849 – volume: 19 start-page: 1114 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0390 article-title: An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy publication-title: Nat. Med doi: 10.1038/nm.3291 – volume: 15 start-page: 1079 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0380 article-title: Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma publication-title: Neuro Oncol doi: 10.1093/neuonc/not082 – volume: 203 start-page: 2691 year: 2006 ident: 10.1016/j.canlet.2016.01.043_bib0560 article-title: Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function publication-title: J. Exp. Med doi: 10.1084/jem.20061104 – volume: 212 start-page: 435 year: 2015 ident: 10.1016/j.canlet.2016.01.043_bib0120 article-title: The interaction of anticancer therapies with tumor-associated macrophages publication-title: J. Exp. Med doi: 10.1084/jem.20150295 – volume: 1 start-page: 54 year: 2011 ident: 10.1016/j.canlet.2016.01.043_bib0110 article-title: Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy publication-title: Cancer Discov doi: 10.1158/2159-8274.CD-10-0028 – volume: 67 start-page: 11021 year: 2007 ident: 10.1016/j.canlet.2016.01.043_bib0570 article-title: Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-2593 – volume: 94 start-page: 1785 year: 1997 ident: 10.1016/j.canlet.2016.01.043_bib0225 article-title: Direct in vivo measurement of targeted binding in a human tumor xenograft publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.94.5.1785 – volume: 21 start-page: 822 year: 2012 ident: 10.1016/j.canlet.2016.01.043_bib0525 article-title: Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer publication-title: Cancer Cell doi: 10.1016/j.ccr.2012.04.025 – volume: 316 start-page: 2713 year: 2010 ident: 10.1016/j.canlet.2016.01.043_bib0055 article-title: Activation of fibroblasts in cancer stroma publication-title: Exp. Cell Res doi: 10.1016/j.yexcr.2010.04.032 – volume: 88 start-page: 268 year: 1994 ident: 10.1016/j.canlet.2016.01.043_bib0275 article-title: Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo publication-title: Br. J. Haematol doi: 10.1111/j.1365-2141.1994.tb05017.x – volume: 11 start-page: 258 year: 1997 ident: 10.1016/j.canlet.2016.01.043_bib0280 article-title: Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis publication-title: Leukemia doi: 10.1038/sj.leu.2400556 – volume: 67 start-page: 7477 year: 2007 ident: 10.1016/j.canlet.2016.01.043_bib0585 article-title: A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-4639 – volume: 98 start-page: 428 year: 2001 ident: 10.1016/j.canlet.2016.01.043_bib0260 article-title: Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration publication-title: Blood doi: 10.1182/blood.V98.2.428 – volume: 116 start-page: 1526 year: 2010 ident: 10.1016/j.canlet.2016.01.043_bib0470 article-title: A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or − dacarbazine in patients with stage IV metastatic melanoma publication-title: Cancer doi: 10.1002/cncr.24821 – volume: 16 start-page: 1812 year: 2010 ident: 10.1016/j.canlet.2016.01.043_bib0565 article-title: Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer publication-title: Clin. Cancer Res doi: 10.1158/1078-0432.CCR-09-3272 – volume: 176 start-page: 1319 year: 1992 ident: 10.1016/j.canlet.2016.01.043_bib0270 article-title: Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression publication-title: J. Exp. Med doi: 10.1084/jem.176.5.1319 – volume: 99 start-page: 4138 year: 2002 ident: 10.1016/j.canlet.2016.01.043_bib0265 article-title: Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk publication-title: Blood doi: 10.1182/blood.V99.11.4138 – volume: 29 start-page: 6115 year: 2010 ident: 10.1016/j.canlet.2016.01.043_bib0320 article-title: Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population publication-title: Oncogene doi: 10.1038/onc.2010.350 – volume: 12 start-page: 253 year: 2012 ident: 10.1016/j.canlet.2016.01.043_bib0140 article-title: Coordinated regulation of myeloid cells by tumours publication-title: Nat. Rev. Immunol doi: 10.1038/nri3175 – volume: 85 start-page: 1033 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0075 article-title: Fibroblast-mediated drug resistance in cancer publication-title: Biochem. Pharmacol doi: 10.1016/j.bcp.2013.01.018 – volume: 3 start-page: 377 year: 2003 ident: 10.1016/j.canlet.2016.01.043_bib0330 article-title: Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells publication-title: Cancer Cell doi: 10.1016/S1535-6108(03)00058-8 – volume: 71 start-page: 2664 year: 2011 ident: 10.1016/j.canlet.2016.01.043_bib0555 article-title: COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-3055 – volume: 21 start-page: 309 year: 2012 ident: 10.1016/j.canlet.2016.01.043_bib0010 article-title: Accessories to the crime: functions of cells recruited to the tumor microenvironment publication-title: Cancer Cell doi: 10.1016/j.ccr.2012.02.022 – volume: 278 start-page: 25285 year: 2003 ident: 10.1016/j.canlet.2016.01.043_bib0340 article-title: Regulation of multidrug resistance in cancer cells by hyaluronan publication-title: J. Biol. Chem doi: 10.1074/jbc.C300173200 – volume: 25 start-page: 911 year: 2007 ident: 10.1016/j.canlet.2016.01.043_bib0130 article-title: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells publication-title: Nat. Biotechnol doi: 10.1038/nbt1323 – volume: 19 start-page: 1264 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0510 article-title: CSF-1R inhibition alters macrophage polarization and blocks glioma progression publication-title: Nat. Med doi: 10.1038/nm.3337 – volume: 156 start-page: 590 year: 2014 ident: 10.1016/j.canlet.2016.01.043_bib0610 article-title: Sensitizing protective tumor microenvironments to antibody-mediated therapy publication-title: Cell doi: 10.1016/j.cell.2013.12.041 – volume: 15 start-page: 520 year: 2009 ident: 10.1016/j.canlet.2016.01.043_bib0420 article-title: Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma publication-title: Clin. Cancer Res doi: 10.1158/1078-0432.CCR-08-1612 – volume: 331 start-page: 1612 year: 2011 ident: 10.1016/j.canlet.2016.01.043_bib0515 article-title: CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans publication-title: Science doi: 10.1126/science.1198443 – volume: 62 start-page: 909 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0580 article-title: Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer publication-title: Cancer Immunol. Immunother doi: 10.1007/s00262-013-1396-8 – volume: 20 start-page: 4995 year: 2001 ident: 10.1016/j.canlet.2016.01.043_bib0315 article-title: Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells publication-title: Oncogene doi: 10.1038/sj.onc.1204554 – volume: 5 start-page: 2208 year: 2014 ident: 10.1016/j.canlet.2016.01.043_bib0375 article-title: Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes publication-title: Oncotarget doi: 10.18632/oncotarget.1893 – volume: 9 start-page: 665 year: 2009 ident: 10.1016/j.canlet.2016.01.043_bib0230 article-title: Environment-mediated drug resistance: a major contributor to minimal residual disease publication-title: Nat. Rev. Cancer doi: 10.1038/nrc2714 – volume: 9 start-page: 974 year: 2014 ident: 10.1016/j.canlet.2016.01.043_bib0425 article-title: Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer publication-title: J. Thorac. Oncol doi: 10.1097/JTO.0000000000000193 – volume: 73 start-page: 2480 year: 2013 ident: 10.1016/j.canlet.2016.01.043_bib0115 article-title: Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-12-3542 – volume: 96 start-page: 2655 year: 2000 ident: 10.1016/j.canlet.2016.01.043_bib0235 article-title: Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1 publication-title: Blood doi: 10.1182/blood.V96.8.2655 |
| SSID | ssj0005475 |
| Score | 2.6921022 |
| SecondaryResourceType | review_article |
| Snippet | •Tumor microenvironment (TME) influences therapeutic response and clinical outcome.•TME mediated resistance results from continuous crosstalk between tumor... Highlights • Tumor microenvironment (TME) influences therapeutic response and clinical outcome. • TME mediated resistance results from continuous crosstalk... The tumor microenvironment significantly influences therapeutic response and clinical outcome. Microenvironment-mediated drug resistance can be induced by... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 61 |
| SubjectTerms | Angiogenesis Animals Antineoplastic Agents - therapeutic use Apoptosis Bone marrow Cancer Cancer therapies Conflicts of interest Cytokines Dendritic cells Drug resistance Extracellular matrix Fibroblasts Gene expression Hematology, Oncology and Palliative Medicine Humans Hypoxia Immunotherapy Medical prognosis Metastasis Microenvironment Molecular Targeted Therapy Neoplasms - drug therapy Neoplasms - metabolism Neoplasms - pathology Resistance Substance abuse treatment Target therapy Tumor Microenvironment - drug effects Tumorigenesis Tumors Vascular endothelial growth factor |
| Title | Tumor microenvironment and therapeutic response |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0304383516300155 https://www.clinicalkey.es/playcontent/1-s2.0-S0304383516300155 https://dx.doi.org/10.1016/j.canlet.2016.01.043 https://www.ncbi.nlm.nih.gov/pubmed/26845449 https://www.proquest.com/docview/1855306645 https://www.proquest.com/docview/1826658935 https://www.proquest.com/docview/1859486090 |
| Volume | 387 |
| WOSCitedRecordID | wos000393256100008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1872-7980 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005475 issn: 0304-3835 databaseCode: AIEXJ dateStart: 19950106 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfYhhAviG86xhQk3qpAHDtO_DhNRXxOSAwoT5bjOBLTlk5JM-3P5_yVlpaygcRLVKV2nNzPPt8ld79D6EXFS0rrkseEMRVTTEEP1orE1GZZEqW5zXL9-iE_OiqmU_7Jl3fvbDmBvGmKy0t-_l-hhnMAtkmd_Qu4h4vCCfgNoMMRYIfj9YDvz2bt-MwE2i1lsYVIyZBsNW5dcOwqVYHS7fjUpvgMxva33oHq9zj7WtvGAHzvm-WXBrARLZKwfbKU-SBSOKaQoAiJ3_qcKnMc6X5TdKVv1tSt8_xPwJVu4NZMoByzJKiOeelXduvJ4Xscd-nLJP5sRjeDY8P3hR1N7wrrNRZdKhKx1nQL7aR5xkF_7Ry8nUzfLcJ5qCVVHh4spEnaWL71-9tkhmxyM6y5cXwX3fF-QnTg8L2HbujmPrr10UdCPECvLMzRKswRwBwtwRwFmB-iL68nx4dvYl_8IlbgI89jUitcE15nNauIyhhXklcSp4mWdV5QKUHTsrqUJjpYqUKWiQTfXEuiszJVYJg8QtvNrNFPUFTwTPJCVyapGhYm5jLJ05JrLrVirMIjRIIshPLM8KZAyakIIYAnwklQGAmKBAuQ4AjFQ69zx4xyRfssiFmErF_YpwTMpSv65b_rpzu_5jqxaa4s9_T2pLMTrzHmXpgHYjFMYUpsMUbhws-Hv0Ebm09sstGz3rQBgzcDH-CPbQxFEkt4MkKP3RwbBGi4lzJK-e4_P_RTdHux4PfQ9rzt9TN0U13Mf3TtPtrKp8W-Xzs_AUUowL8 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tumor+microenvironment+and+therapeutic+response&rft.jtitle=Cancer+letters&rft.au=Wu%2C+Ting&rft.au=Dai%2C+Yun&rft.date=2017-02-28&rft.issn=0304-3835&rft.volume=387&rft.spage=61&rft.epage=68&rft_id=info:doi/10.1016%2Fj.canlet.2016.01.043&rft.externalDBID=ECK1-s2.0-S0304383516300155&rft.externalDocID=1_s2_0_S0304383516300155 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F03043835%2FS0304383516X00298%2Fcov150h.gif |